Sinusoidal Injury and Portal Hypertension after Hepatectomy for Colorectal Liver Metastases: Predictors, Risk Stratification, and Clinical Outcomes

Sinusoidal Injury and Portal Hypertension after Hepatectomy for Colorectal Liver Metastases: Predictors, Risk Stratification, and Clinical Outcomes | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Sinusoidal Injury and Portal Hypertension after Hepatectomy for Colorectal Liver Metastases: Predictors, Risk Stratification, and Clinical Outcomes XAVIER HERNANDEZ-YAGÜE, SANTIAGO LÓPEZ-BEN, ANA AULA-OLIVAR, WALTER CARBAJAL-OCHOA, and 8 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8196994/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 10 You are reading this latest preprint version Abstract INTRODUCTION Sinusoidal obstruction syndrome (SOS) and early portal hypertension (ePHT) represent significant hepatic vascular complications following preoperative chemotherapy and liver resection for colorectal liver metastases (CRLM). This study aimed to identify predictors of SOS and ePHT and to develop a risk model for preoperative stratification. METHODS A retrospective analysis was conducted in 108 patients undergoing hepatectomy for CRLM after ≥ 4 cycles of neoadjuvant chemotherapy combined with anti-EGFR or anti-VEGF therapy. SOS severity was graded histologically, and ePHT was defined by thrombocytopenia, splenomegaly, varices, or ascites within 3 months postoperatively. Logistic regression models identified predictors of moderate-to-severe SOS (G2–3) and ePHT. Predictive performance was assessed using receiver operating characteristic (ROC) analysis. RESULTS Moderate-to-severe SOS occurred in 24.07% of patients and ePHT in 21.3%. Independent predictors of SOS were anti-VEGF therapy (protective, OR = 0.214; 95% CI 0.075–0.610; p = 0.004) and preoperative portal vein embolization (PVE) or ligation (risk factor, OR = 2.819; 95% CI 1.019–7.796; p = 0.046). The SOS predictive model showed good discrimination (AUC = 0.75). For ePHT, major hepatectomy (OR = 7.78; 95% CI 2.32–25.99; p < 0.001) and the calculated probability of SOS G2–3 (OR = 40.82; 95% CI 2.60–640.53; p = 0.008) were independent predictors (AUC = 0.80; specificity = 84.3%). Neither SOS nor ePHT significantly affected 90-day mortality (8.3%) or overall survival (p > 0.05). CONCLUSIONS Major hepatectomy and chemotherapy-induced sinusoidal injury are key determinants of ePHT after CRLM resection. Anti-VEGF therapy exerts a protective endothelial effect, while PVE increases risk. Despite their incidence, neither SOS nor ePHT compromised survival, suggesting reversibility with optimized perioperative management. Figures Figure 1 Figure 2 INTRODUCTION Liver resection for colorectal cancer liver metastases (CRLM) after neoadjuvant chemotherapy is an established curative strategy. While the short-term toxicities of systemic therapy are well described, its long-term hepatic consequences among cancer survivors remain poorly characterized. The liver is the predominant site of metastasis in metastatic colorectal cancer (mCRC), and resection remains the only potentially curative treatment(1). Patients with resectable or borderline-resectable CRLM often receive intensive conversion chemotherapy to achieve operability (2–4). However, in the pursuit of resectability, the deleterious hepatic effects of chemotherapy—both immediate and delayed—are frequently underestimated. Understanding chemotherapy-induced hepatotoxicity is essential to assess perioperative risks (i.e., bleeding, ascites), postoperative outcomes (i.e., portal hypertension, hepatic failure), and long-term surveillance needs. Robinson et al. provided a comprehensive meta-analysis of chemotherapy-related liver injury in resected CRLM (5). Three major histopathological entities can be identified: Hepatic Steatosis Characterized by intrahepatocellular fat accumulation, steatosis is graded as 0 = absent, 1 = mild (0–33%), 2 = moderate (33–66%), and 3 = severe (>66%) (6). Severe steatosis (>30%) triples postoperative mortality after major hepatectomy (>3 segments) (7). However, meta-analyses show no consistent association between chemotherapy for CRLM and severe steatosis (5). Steatohepatitis Defined by fatty infiltration with inflammatory changes and hepatocellular ballooning (Brunt EM criteria) (8), steatohepatitis may progress to fibrosis, cirrhosis, and hepatic failure. Risk factors include type 2 diabetes, metabolic syndrome, and obesity (BMI >35 kg/m²). Ninety-day postoperative mortality is significantly higher in affected patients (OR 10.5; 95% CI 2.0–36.4; p = 0.001) (9). Irinotecan markedly increases this risk (RR 3.45; 95% CI 1.12–10.62; p = 0.03), while oxaliplatin does not (RR 1.17; 95% CI 0.45–3.04; p = 0.75). Sinusoidal Injury Graded from 0 (absent) to 3 (severe, full-lobular involvement) (10), sinusoidal injury progresses from dilatation and hepatocellular atrophy to perisinusoidal fibrosis and nodular regenerative hyperplasia. Moderate-to-severe injury (grades 2–3) is not associated with increased postoperative mortality (OR 1.21; 95% CI 0.23–6.35; p = 0.82) (11). However, oxaliplatin significantly increases the risk, especially after ≥6 cycles (RR 3.20; 95% CI 1.01–10.13; p = 0.048) (12). In contrast irinotecan does not appear to increase this risck (5). Bevacizumab co-administration reduces the incidence of sinusoidal injury (HR 0.50; 95% CI 0.37–0.67; p < 0.00001) but does not significantly lower postoperative hepatic failure (HR 0.61; 95% CI 0.34–1.07; p = 0.08) (13). Advanced nonalcoholic steatohepatitis (NASH) with fibrosis increases all-cause mortality proportionally to fibrosis stage (14). Five-year survival may be significantly lower in patients with moderate-to-severe sinusoidal injury (HR 2.52; 95% CI 1.25–5.50; p = 0.010) (15). Given these findings, structured long-term surveillance is warranted for patients undergoing hepatic resection for CRLM, most of whom have received perioperative chemotherapy. Preventive strategies—including metabolic control, weight optimization, and regular hepatic imaging—should be integrated into multidisciplinary follow-up protocols in collaboration with hepatology specialists. Early detection and treatment of complications (i.e., non-selective beta-blockers, endoscopic ligation) are essential to improve long-term outcomes. This study analyzes medium- and long-term hepatic complications following chemotherapy for CRLM and discusses their clinical implications for follow-up. MATERIALS AND METHODS Hypothesis and Study Objectives The primary objective was to identify factors associated with the development of hepatic sinusoidal injury (Sinusoidal Obstruction Syndrome, SOS) and the occurrence of early clinical manifestations of portal hypertension (ePHT) (defined as those appearing within the first three monts after hepatic surgery) in patients undergoing liver surgery for colorectal cancer liver metastases (CRLM) following preoperative systemic therapy. The secondary objective was to evaluate the impact of SOS and ePHT on overall survival (OS), providing the rationale for targeted long-term surveillance in this population. Additionally, a risk calculator for predicting SOS or early portal hypertension will be developed in Microsoft Excel format to enable clinical use and facilitate external validation by other research groups. This investigation represents a secondary analysis derived from a previously published study originally powered to assess pathological tumor response—specifically, the degree of chemotherapy-induced fibrosis—in patients treated with epidermal growth factor receptor (anti-EGFR) versus vascular endothelial growth factor (anti-VEGF) inhibitor–based regimens( 16 ). Study Design and Population This retrospective, registry-based study included patients who underwent hepatic resection for CRLM after at least four cycles of preoperative chemotherapy combined with targeted therapy (anti-Epidermal Growth Factor Receptor (anti-EGFR) or anti-Vascular Endotelial Growth Factor (anti-VEGF)) at the Hospital Universitari de Girona Dr. Josep Trueta. The study was approved by the institutional ethics committee (code: 2019.130) and conducted in accordance with the Declaration of Helsinki. All surviving patients gave written informed consent for participation in the study. Inclusion criteria were: 1. Histologically confirmed colorectal adenocarcinoma, 2. Liver metastases deemed resectable or potentially resectable by a multidisciplinary tumor board (MDT), 3. Receipt of ≥ 4 cycles of neoadjuvant chemotherapy plus anti-EGFR or anti-VEGF therapy, 4. R0 liver resection (complete macroscopic and microscopic clearance), regardless of concurrent resection of extrahepatic disease. Based on these criteria, 108 patients were included in the final analysis. For the primary endpoint, all patients underwent thoracoabdominal computed tomography and complete blood count at 3 months post-hepatectomy. Exclusion criteria were: 1. Preoperative platelet count 12 cm on CT scan, 3. Radiologic or clinical evidence of ascites or esophagogastric varices before surgery. Definitions and Clinical Criteria Early portal hypertension (ePHT) was defined as the presence of any of the following within 3 months after liver resection: platelet count 12 cm (maximum diameter on CT), or radiological/clinical ascites. Preoperative hepatopathy was graded as follows: 0 = none (no history of liver disease), 1 = mild (abnormal liver enzymes, negative viral serology, no imaging evidence of chronic disease), 2 = moderate (abnormal enzymes ± viral positivity, imaging or clinical evidence of chronic disease without cirrhosis), 3 = severe (liver cirrhosis of any etiology, Child–Pugh A). Clinical Risk Score (CRS) was calculated according to Fong et al. and categorized as low (0–2) or intermediate/high ( 3 – 5 )( 17 ). Lymph Node Ratio (LNR) was defined as the ratio of positive regional lymph nodes to the total number retrieved in the colectomy or rectal resection specimen. Liver failure was defined according to the International Study Group of Liver Surgery (ISGLS) and categorized as NO or YES (Grades A, B or C)( 18 ). Statistical Analysis Sample size The original study design was powered to detect a difference in the proportion of patients achieving ≥ 40% tumor fibrosis between EGFR inhibitor– and VEGF inhibitor–based regimens. Based on this endpoint, 52 patients per group (total N = 104) were required for adequate power( 16 ). The current analysis, focusing on SOS and ePHT, was exploratory and hypothesis-generating. Statistical methods Categorical variables were summarized as absolute frequencies and percentages, and compared using the Chi-square or Fisher’s exact test, as appropriate. Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range (IQR), depending on data distribution. Normality was assessed using the Shapiro–Wilk test. Parametric data were analyzed using Student’s t test (two groups) or ANOVA (multiple groups); nonparametric data were analyzed using the Mann–Whitney U or Kruskal–Wallis test. Binary logistic regression models were constructed to identify factors associated with moderate-to-severe SOS (grade 2–3) or ePHT. Variables with p ≤ 0.10 in univariate analysis and those deemed clinically relevant were entered into multivariate models. Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curves and calculation of the Area Under the Curve (AUC). Using the risk and protective coefficients of the variables included in the multivariate model for grade 2–3 sinusoidal obstruction syndrome (SOS), the individual probability of developing SOS G2–3 was calculated for each patient. This derived variable, termed Calculated Probability to SOS G2–3 ), was subsequently incorporated as a preoperative informative variable into the early portal hypertension (ePHT) risk prediction model. To prevent multicollinearity, the covariates used in the derivation of the Calculated Probability to SOS G2–3 were excluded from the multivariate logistic regression model evaluating independent predictors of early portal hypertension (ePHT). Overall survival was analyzed using Kaplan–Meier estimates and compared using the log-rank test. A two-tailed p value < 0.05 was considered statistically significant. All analyses were performed using SPSS (IBM Corp., Armonk, NY) and R statistical software. RESULTS 1. Descriptives 1.1 Clinical and Treatment-Related Characteristics by Sinusoidal Obstruction Syndrome Severity (Grades 0–1 vs. 2–3) ( Table 1 ) A total of 108 patients with colorectal liver metastases (CRLM) who underwent hepatic resection were included from September 2005 to January 2023. The median age was 63 years [IQR 56–70] and the median body mass index (BMI) was 25.1 kg/m² [IQR 22.9–27.0], with no significant differences between groups. No significant differences were observed between groups regarding primary tumor location, metastasis distribution, timing of metastasis, preoperative hepatopathy, lymph node ratio, or the type and cumulative dose of systemic chemotherapy. RAS/BRAF mutations were identified in 39.4% of patients, showing a trend toward lower prevalence in those with higher-grade sinusoidal obstruction (26.9% vs. 43.6%), although this difference did not reach statistical significance (p = 0.100). In contrast, the use of targeted agents demonstrated significant differences: anti-VEGF were significantly less frequent among patients with high-grade sinusoidal obstruction (23.1% vs. 58.5%) (p = 0.001). The number of monoclonal antibody cycles did not differ significantly between groups (p = 0.406). According to the Fong Clinical Risk Score, 61.7% of patients were classified as high-risk (score 3–5) and 38.3% as low-risk (score 0–2), with no significant difference between groups (p = 0.395). 1.2 Surgical and Pathological Outcomes by Sinusoidal Obstruction Syndrome Severity (Grades 0–1 vs. 2–3) ( Table 2 ) Preoperative portal vein embolization (PVE) or ligation emerged as the only factor significantly associated with the development of moderate-to-severe SOS (42.3% vs. 22.0%, p = 0.040). In contrast, no other clinical, operative, or pathological variables demonstrated a significant relationship with SOS severity. Neither patient demographics, tumor characteristics, nor the timing of metastasis showed meaningful differences between groups. Postoperative outcomes did not differ significantly by SOS status. Rates of biliary fistula (8.3%), hemoperitoneum (11.1%), ascites (13.9%), and post-hepatectomy liver failure (13.9%) were comparable (p > 0.05). Major complications (Dindo–Clavien grades 3–5)( 19 ) occurred in 25.9% of patients, and the 90-day mortality rate was 8.3%, with no significant group differences (p = 0.182 and 0.372, respectively). 1.3 Clinical and Treatment-Related Characteristics by Early Portal Hypertension (NO vs. YES). Table 3 Table 3 summarizes the clinical, pathological, and treatment-related characteristics of the 108 patients included in the study, stratified according to the development of early clinical portal hypertension (ePHT), which occurred in 21.3% of cases (n = 23). Baseline demographic and clinical variables, including sex distribution, age at surgery, body mass index, baseline hepatopathy, and Fong Clinical Risk Score, were comparable between groups (all p > 0.05). Similarly, the type of chemotherapy backbone (oxaliplatin- vs. irinotecan-based), the number of cycles, and cumulative drug doses showed no significant association with the development of ePHT. Among perioperative factors, preoperative portal vein embolization or ligation was significantly more frequent in patients who developed ePHT (47.8% vs. 21.2%, p = 0.022). Hepatic inflow occlusion time (clamping time) showed a non-significant trend toward longer duration in the ePHT group (median 54.5 vs. 35.0 minutes, p = 0.054). With respect to targeted therapy, patients who developed ePHT more frequently received less frequently anti-VEGF inhibitors (34.8% vs. 54.1%), though these differences did not reach statistical significance (p = 0.158). Reintervention rates, pathological tumor response, and other postoperative parameters were likewise similar across groups. Histopathological assessment revealed a significantly higher proportion of grade 2–3 sinusoidal obstruction syndrome (SOS) among patients with ePHT (p < 0.001). Based on its strong statistical association and potential preoperative predictive value, a derived variable— Calculated Probability to SOS G2–3 —was generated from the multivariate SOS prediction model. This variable also differed significantly between ePHT groups (ePHT = YES: median risk = 0.30 [0.14–0.49] vs ePHT = NO: median risk = 0.21 [0.08–0.26], p = 0.018) and was included in the logistic regression model for early portal hypertension prediction. 3. Predictive Model for Sinusoidal Obstruction Syndrome (SOS) A logistic regression analysis was performed to identify clinical and therapeutic factors associated with the development of moderate-to-severe sinusoidal obstruction syndrome (SOS grades 2–3) following hepatic resection in patients previously treated with neoadjuvant chemotherapy. 3.1 Univariate Analysis ( Table 4 ) In univariate analysis, no significant association was observed between the occurrence of SOS G2–3 and sex, age at surgery, or chemotherapy backbone (oxaliplatin- vs. irinotecan-based), all p > 0.05. The number of chemotherapy cycles showed a trend toward increased risk of sinusoidal injury with each additional cycle (OR = 1.08; 95% CI: 1.00–1.16; p = 0.056). The cumulative oxaliplatin dose was associated with the presence of SOS G2–3 (p = 0.043). The use of anti-VEGF therapy before liver surgery was significantly associated with a lower risk of SOS G2–3 compared with anti-EGFR therapy (OR = 0.22; 95% CI: 0.07–0.58; p = 0.002). Conversely, portal vein embolization or ligation tended to increase the risk of SOS (OR = 2.58; 95% CI: 0.99–6.69; p = 0.052). No significant associations were found for pathological tumor response (Rubbia–Brandt or Poulsides criteria( 20 )), baseline hepatopathy, body mass index, extent of necrosis, or Fong Clinical Risk Score (all p > 0.05). 3.2 Multivariate Analysis ( Table 4 ) Independent predictors of moderate-to-severe SOS were identified as follows: Use of anti-VEGF therapy (protective factor): OR = 0.214; 95% CI: 0.075–0.610; p = 0.004, Portal vein embolization or ligation (risk factor): OR = 2.819; 95% CI: 1.019–7.796; p = 0.046 and Number of chemotherapy cycles (trend, not statistically significant): OR = 1.085; 95% CI: 0.998–1.180; p = 0.055. The cumulative oxaliplatin dose did not demonstrate predictive value in the multivariate model for grade 2–3 sinusoidal obstruction syndrome (SOS) (OR = 0.99, 95% CI 0.992–1.007, p = 0.814). This predictive algorithm for moderate-to-severe sinusoidal obstruction demonstrated a sensitivity of 75% (n = 6/8), a specificity of 80% (n = 80/100), and an AUC of 0.750 (95% CI: 0.627–0.874; standard error (SE) = 0.062) on the ROC curve (Fig. 1 -A). 4. Predictive Model for Early Clinical Portal Hypertension (ePHT) A logistic regression analysis was performed to identify factors associated with the development of early clinical portal hypertension (ePHT) after hepatic resection in patients who had received neoadjuvant chemotherapy. 4.1 Univariate Analysis ( Table 5 ) In univariate analysis, neither sex ( p = 0.418) nor age at liver surgery ( p = 0.605) was significantly associated with ePHT. No significant associations were observed for chemotherapy regimen ( p = 0.202), cumulative chemotherapy dose ( p = 0.382), or monoclonal antibody type ( p = 0.108). Portal vein embolization or ligation was more frequent among patients who developed ePHT (OR = 0.30; 95% CI: 0.11–0.80; p = 0.016). Major hepatectomy showed a strong association with ePHT (OR = 7.52; 95% CI: 2.53–28.6; p < 0.001). Longer hepatic clamping time showed a nonsignificant trend toward increased risk ( p = 0.225). Histopathological variables—including fibrosis, tumor necrosis, and pathological tumor response according to Rubbia–Brandt or Poulsides criteria—were not associated with ePHT ( p > 0.05). Conversely, the composite variable Calculated Probability to SOS G2–3 was significantly associated with clinical ePHT (OR = 44.3; 95% CI: 3.44–570.3; p = 0.004). 4.2 Multivariate Analysis ( Table 5 ) After adjusting for potential confounders, two independent predictors remained significantly associated with the occurrence of clinical HTP: Major hepatectomy: OR = 7.78; 95% CI: 2.33–25.99; p < 0.001; and Calculated Probability to SOS G2–3 : OR = 40.82; 95% CI: 2.60–640.53; p = 0.008. No additional clinical, surgical, or pathological variables showed independent associations. This predictive model for clinical portal hypertension achieved a sensitivity of 25% (n = 4/12), a specificity of 84.3% (n = 81/96), and an AUC of 0.796 (95% CI: 0.690–0.902; SE = 0.053) (Fig. 1 -B). 4. Overall Survival The Kaplan–Meier analysis of overall survival showed no significant differences between patients with mild or no sinusoidal obstruction (SOS grade 0–1) and those with moderate to severe sinusoidal obstruction (SOS grade 2–3). The median overall survival was 29 months (95% CI, 23.31–34.68) for the SOS 0–1 group and 28 months (95% CI, 5.37–50.62) for the SOS 2–3 group (log-rank p = 0.59) (Fig. 2 -A). Similarly, overall survival did not differ significantly according to the presence of clinical features of early portal hypertension. The median overall survival was 27 months (95% CI, 23.08–30.91) among patients without clinical ePHT, compared with 46 months (95% CI, 27.36–64.63) among those who developed clinical signs of ePHT (log-rank p = 0.37) (Fig. 2 -B). DISCUSSION In this retrospective study, we evaluated clinical, pathological, and therapeutic factors associated with the development of early clinical portal hypertension (ePHT) after hepatic resection for colorectal liver metastases (CRLM), as well as its relationship with chemotherapy-induced sinusoidal obstruction syndrome (SOS). Although Portal Hypertension is an uncommon but potentially serious postoperative complication, our findings indicate that it primarily results from the combined effect of extensive hepatic resection and pre-existing sinusoidal injury secondary to neoadjuvant chemotherapy exposure. The analysis of factors associated with moderate-to-severe SOS identified two main determinants: the use of anti-VEGF therapy, which exerted a protective effect, and preoperative portal vein embolization or ligation, which significantly increased the risk. A higher number of chemotherapy cycles also showed a trend toward greater sinusoidal injury, although without reaching statistical significance. These results are consistent with previous studies describing the multifactorial nature of chemotherapy-induced hepatic vascular injury( 21 ) and emphasize the importance of optimizing neoadjuvant regimens to minimize sinusoidal damage prior to surgery. Oxaliplatin-based chemotherapy has long been recognized as a major contributor to sinusoidal injury through endothelial dysfunction and increased sinusoidal resistance( 22 ). In our series, cumulative oxaliplatin exposure correlated with SOS in univariate analysis, but this association did not persist in the multivariate model, suggesting that the risk may be modulated by additional factors, particularly the type of biologic agent used. The protective effect observed with VEGF inhibitors aligns with their endothelial-stabilizing, anti-angiogenic mechanism, which may counteract sinusoidal dilatation and congestion( 23 ). Multivariate analysis revealed that the two independent predictors of postoperative ePHT were major hepatectomy and the calculated probability of developing moderate-to-severe SOS. Major hepatectomy increased the risk of Portal Hypertension nearly eightfold, underscoring the hemodynamic consequences of extensive parenchymal loss and reduced hepatic vascular compliance. These findings are consistent with previous reports linking reduced functional remnant liver volume to increased portal pressure following major resection( 24 ). The strong association between the predicted probability of SOS grades 2–3 and the occurrence of ePHT further supports the pathophysiological connection between chemotherapy-induced vascular injury and impaired hepatic microcirculation. The predictive model for ePHT showed good overall discrimination (AUC = 0.796) and high specificity (84.3%), although sensitivity remained modest (25%), reflecting the relatively low prevalence of ePHT in this cohort (21%). This limitation likely mirrors the multifactorial nature of postoperative portal hypertension, in which mechanical, vascular, and regenerative factors interact. Nonetheless, the model represents a valuable clinical tool for preoperative risk stratification, particularly among patients who receive prolonged or intensive neoadjuvant chemotherapy. To facilitate clinical application, a risk calculator predicting the probability of developing grade 2–3 SOS and ePHT was generated using the regression coefficients derived from both multivariate logistic models (Fig. 1 . supplementary). Given the high specificity of the early portal hypertension predictive model, it can be concluded that the test reliably identifies patients with a low likelihood of developing ePHT. In such patients, exceptional preoperative interventions or intensive postoperative surveillance aimed at detecting and managing portal hypertension in long-term survivors may not be necessary. In contrast, for patients with a high predicted probability of ePHT, preoperative strategies to mitigate this risk should be carefully considered. These may include limiting the number of preoperative chemotherapy cycles, encouraging the use of anti-VEGF therapy, avoiding portal vein embolization, or opting for less extensive hepatic resections when feasible. If modification of these risk factors is not possible, these patients should be enrolled in a structured postoperative follow-up program focused on the early detection and prompt management of portal hypertension, should it occur. It is also important to note that, given the model’s sensitivity of 25%, only about one in four patients is expected to actually develop early stigmata of portal hypertension. In this context, it would be essential to prospectively establish and validate a threshold risk value for ePHT development to guide treatment decisions and minimize the risk of early postoperative portal hypertension. As reported by the Johns Hopkins University group (Baltimore, MD, USA), 90-day mortality has been proposed as a more reliable indicator of surgery-related mortality following hepatic resection( 25 ). In our series, the 90-day mortality rate was 8.3% (Table 2 ), which may appear higher than expected. However, this cohort represented a high-risk population, with 70.4% (n = 76) of patients initially deemed technically unresectable due to extensive tumor burden and the anticipated need for major hepatectomy, frequently combined with prior portal vein embolization or ligation. This high level of surgical complexity likely accounts for the relatively elevated postoperative mortality observed. Despite the association between sinusoidal obstruction syndrome (SOS) and early portal hypertension (ePHT), neither condition significantly influenced postoperative morbidity, 90-day mortality, nor long-term overall survival. These findings are consistent with previous reports indicating that sinusoidal injury, while common, does not necessarily compromise postoperative or oncologic outcomes when perioperative management is optimized( 26 ). The absence of survival differences between patients with and without ePHT further suggests that the development of clinical stigmata of portal hypertension does not inherently indicate irreversible hepatic dysfunction or reduced oncologic efficacy. Our findings also highlight the complex role of preoperative portal vein embolization (PVE), which was associated with both a higher risk of SOS and increased incidence of ePHT in univariate analyses. Although PVE facilitates hypertrophy of the future liver remnant, it may exacerbate portal pressure gradients and sinusoidal stress, particularly in livers previously exposed to cytotoxic chemotherapy. In such patients, the indication for PVE should be carefully considered, and postoperative surveillance for portal hypertension should be intensified. This study has several limitations. Its retrospective, single-center design and the relatively small number of patients developing clinical ePHT may have limited the statistical power of the analyses. The diagnosis of portal hypertension was based on clinical and radiological criteria rather than direct hemodynamic measurements, which may underestimate subclinical cases. Moreover, many patients undergoing hepatic resection for CRLM subsequently received adjuvant chemotherapy—often oxaliplatin-based—preventing the assessment of late-onset manifestations of portal hypertension. Despite these limitations, the consistent association between SOS and HTP across analyses supports a biologically plausible relationship with clear clinical relevance. Notably, although subsequent systemic or surgical treatments in patients with recurrent hepatic disease were not analyzed, the potential development of late-onset portal hypertension did not appear to negatively influence overall survival in this cohort. Conclusions In summary, major hepatectomy and moderate-to-severe sinusoidal obstruction syndrome are the principal determinants of clinical early portal hypertension after liver resection in patients with CRLM treated with neoadjuvant chemotherapy. Anti-VEGF therapy appear to confer a protective effect against sinusoidal injury, whereas preoperative PVE may increase the risk of hepatic vascular complications. Importantly, the occurrence of ePHT did not negatively affect long-term survival, suggesting that, with appropriate perioperative management, its impact may be largely reversible. Prospective studies incorporating direct portal pressure measurements are warranted to validate these results and further refine predictive models for postoperative ePHT. Declarations Competing Interests: The authors declare no competing interest. FUNDING: This research was funded by the Agrupacio de Ciències Mèdiques i de la Salut de Girona Grant. Author Contribution Conceptualization, X.H-Y, S.L-B and J.F i F.; Methodology, X.H-Y, S.L-B, A.A-O, J.M-S, MT. A-Q, M.R.O-D, L.F-V, M.B-P, C.M-M, and J.F i F; Software, J.M-S, M.B-P, G. O-G. and J.F i F.; Validation, X.H-Y, S.L-B, W.C-O, J.M-S, M.R.O-D, M.B-P. and J.F i F.; Formal analysis, X.H-Y, J.M-S, M.R.O-D., G.O-G, M.B-P. and J.F i F.; Investigation, X.H-Y. and J.F i F.; Resources, X.H-Y, S.L-B, A.A-O, J.M-S, MT. A-Q, M.R.O-D, L.F-V, M.B-P, C.M-M, and J.F i F; Data curation, X.H-Y., S.L-B, W.C-O and J.M-S. All authors have reviewed and agreed to the uploaded version of the manuscript. Data Availability The data supporting the findings of this study can be obtained by contacting the corresponding author upon request. References Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al (2012) The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. Oncologist [Internet]. ;17(10):1225–39. Available from: https://academic.oup.com/oncolo/article/17/10/1225/6400912 Innominato PF, Cailliez V, Allard MA, Lopez-Ben S, Ferrero A, Marques H et al (2022) Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers (Basel). ;14(17) Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT et al (2010) Articles Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol [Internet] 11:38–47 Available from: www.thelancet.com/oncology Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T et al (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22(9):2042–2048 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis. 19:4287–4299Annals of Surgical Oncology Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313–1321 De Meijer VE, Kalish BT, Puder M, IJzermans JNM (2010) Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 97:1331–1339 Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072 Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460–466 Van Mierlo KMC, Zhao J, Kleijnen J, Rensen SS, Schaap FG, Dejong CHC et al (2016) The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis. Surg Oncol 25(3):298–307 Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247(1):118–124 Volk AM, Fritzmann J, Reissfelder C, Weber GF, Weitz J, Rahbari NN (2016) Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases. BMC Cancer. ;16(1) Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease. Systematic Review and Meta-Analysis Tamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18(2):421–430 Hernández-Yagüe X, López-Ben S, Martínez-Sancho J, Ortíz-Durán MR, Casellas-Robert M, Aula-Olivar A et al (2025) The Prognostic Value of Tumor Fibrosis in Patients Undergoing Hepatic Metastasectomy for Colorectal Cancer: A Retrospective Pooled Analysis. Cancers (Basel). ;17(11) Fong Y, Fortner J, Sun RL, † M, Brennan F, Blumgart LH Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer Analysis of 1001 Consecutive Cases. Vol. 230, ANNALS OF SURGERY Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R et al (2011) Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149(5):713–724 Clavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al (2009) The clavien-dindo classification of surgical complications: Five-year experience. 250:187–196Annals of Surgery Poultsides GA, Bao F, Servais EL, Hernandez-Boussard T, Dematteo RP, Allen PJ et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: Fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19(9):2797–2804 Robinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F et al Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model Puente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M et al (2019) Porto-sinusoidal vascular disease associated to oxaliplatin: An entity to think about it, vol 8. Cells. MDPI Knitter S, Duwe G, Beierle AS, Pesthy S, Ritschl PV, Hillebrandt KH et al (2022) Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice. Cancers (Basel). ;14(23) Carrapita JG, Rocha C, Donato H, Costa A, Abrantes AM, Santos JN et al (2019) Portal venous pressure variation during hepatectomy: A prospective study. Acta Med Port 32(6):420–426 Mayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB 13(7):473–482 Robinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis. 19:4287–4299Annals of Surgical Oncology Tables Table 1 CLINICAL AND SYSTEMIC TREATMENT CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID − 2 CATEGORIES [ALL] N = 108 SOS a G 0–1 N = 82 SOS a G 2–3 N = 26 p.overall AGE AT LIVER SURGERY (years) 63.00 [56.00;70.00] 63.00 [56.00;70.00] 65.00 [55.7–71.2] 0.527 GENDER MEN 67 (62.0%) 50 (61.0%) 17 (65.4%) 0.436 WOMAN 41 (38.0%) 32 (39.0%) 9 (34.6%) PRIMARY TUMOR LOCATION (RIGHT vs LEFT) RIGHT COLON 17 (15.7%) 14 (17.1%) 3 (11.5%) 0.370 LEFT COLON 91 (84.3%) 68 (82.9%) 23 (88.5%) LYMPH NODE RATIO 0.059 [0.000;0.142] 0.057 [0.003;0.120] 0.076 [0.000;0.290] 0.462 MAJOR SIZE OF LIVER METASTASES (mm) 45.00 [27.00;60.75] 45.00 [27.00;55.00] 50.00 [27;80] 0.769 SINCRONICAL vs METACRONICAL LIVER METASTASES SINCRONICAL 83 (76.9%) 61 (74.4%) 22 (84.6%) 0.212 METACRONICAL 25 (23.1%) 21 (25.6%) 4 (15.4%) UNI OR BILOBAR LIVER METASTASES UNILOBAR 58 (53.7%) 43 (52.4%) 15 (57.7%) 0.405 BILOBAR 50 (46.3%) 39 (47.6%) 11 (42.3%) CLINICAL RISK SCORE-FONG (2 CATEGORIES) CLINICAL RISK SCORE 0–2 36 (38.3%) 29 (39.7%) 7 (33.3%) 0.395 CLINICAL RISK SCORE 3–5 58 (61.7%) 44 (60.3%) 14 (66.7%) HEPATOPATHY PRIOR TO LIVER SURGERY NONE OR MILD HEPATOPATHY 54 (53.5%) 39 (51.3%) 15 (60.0%) 0.301 MODERATE OR SEVERE HEPATOPATHY 47 (46.5%) 37 (48.7%) 10 (40.0%) BODY MASS INDEX (BMI) 25.08 [22.95;27.04] 25.22 [23.34;27.34] 24.67 [22.43;26.59] 0.600 RAS/BRAF MUTATIONS YES 41 (39.4%) 34 (43.6%) 7 (26.9%) 0.100 NO 63 (60.6%) 44 (56.4%) 19 (73.1%) CHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY OXALIPLATIN 69 (63.9%) 52 (63.4%) 17 (65.4%) 0.525 IRINOTECAN 39 (36.1%) 30 (36.6%) 9 (34.6%) NUMBER OF CHEMOTHERAPY CICLES BEFORE LIVER SURGERY 7.00 [5.00;11.00] 7.00 [5.00;10.25} 7.50 [5.00;13.50] 0.750 CUMULATIVE DOSE OF OXALIPLATIN (mg/m2) 544.00 [354.88;841.50] 541.45 [366.56;787.31] 544.00 [340.00;1317.50] 0.661 CUMULATIVE DOSE OF IRINOTECAN (mg/m2) 1260.00 [1071.00;1800.00] 1260.00 [1053.0;1786.50] 1440.00 [1071.00;1944.00] 0.635 CUMULATIVE DOSE OF CHEMOTHERAPY (mg/m2) 819.00 [463.25;1271.25] 779.88 [459.00;1260.0] 1071.00 [463.25;1017.00] 0.371 Table 1 ( cont ). CLINICAL AND SYSTEMIC TREATMENT CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID − 2 CATEGORIES [ALL] N = 108 SOS a G 0–1 N = 82 SOS a G 2–3 N = 26 p.overall MONOCLONAL ANTIBODY BEFORE LIVER SURGERY EGFR inhibidtor 54 (50%) 34 (41.5%) 20 (76.9%) 0.001 VEGF inhibitor 54 (50%) 48 (58.5%) 6 (23.1%) NUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY 6.00 [4.00;9.00] 6.00 [4.00;9.0] 7.00 [4.00;12.00] 0.406 a Sinusoidal Obstruction Syndrome Table 2 SURGERY AND PATHOLOGIC RELATED CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID − 2 CATEGORIES [ALL] N = 108 SOS a G 0–1 N = 82 SOS a G 2–3 N = 26 p.overall TIME FROM NEOADJUVANT THERAPY TO LIVER SURGERY (weeks) 5.00 [4.00;8.75] 5.00 [4.00;9.00] 5.00 [3.00;9.25] 0.723 EMBOLIZATION OR PORTAL LIGATION BEFORE LIVER SURGERY NO 79 (73.1%) 64 (78.0%) 15 (57.7%) 0.040 YES 29 (26.9%) 18 (22.0%) 11 (42.3%) TYPES OF LIVER SURGERY MINOR HEPATECTOMY 57 (52.8%) 44 (53.7%) 13 (50.0%) 0.459 MAJOR HEPATECTOMY 51 (47.2%) 38 (46.3%) 13 (50.0%) LIVER SURGERY DURATION (min) 267.50 [185.00;330.00] 265.00 [180.00;316.25] 307.50 [223.00;405.00] 0.119 HEPATIC CLAMPING TIME (min) 38 [17.50;81.50] 35.00 [15.00;76.00] 49.00 [24.75;89.25] 0.120 BLOOD LOSS DURING HEPATIC SURGERY (mL) 648.00 [317.50;1080.00] 646.00 [320.00;913.00] 778.00 [243.00;1391.00] 0.682 POST-SURGICAL BILIARY FISTULA YES 9 (8.3%) 7 (8.5%) 2 (7.7%) 0.628 NO 99 (91.7%) 75 (91.5%) 24 (92.3%) HEMOPERITONEUM YES 12 (11.1%) 9 (11.0%) 3 (11.5%) 0.590 NO 96 (88.9%) 73 (89.0%) 23 (88.5%) LIVER FAILURE YES 15 (13.9%) 13 (15.9%) 2 (7.7%) 0.242 NO 93 (86.1%) 69 (84.1%) 24 (92.3%) POST-SURGICAL ASCITES YES 15 (13.9%) 11 (13.4%) 4 (15.4%) 0.512 NO 93 (86.1%) 71 (86.6%) 22 (84.6%) DINDO-CLAVIEN (2 CATEGORIES) DINDO-CLAVIEN 0–2 80 (74.1%) 63 (76.8%) 17 (65.4%) 0.182 DINDO-CLAVIEN 3–5 28 (25.9%) 19 (23.2%) 9 (34.6%) 90-DAYS MORTALITY YES 9 (8.3%) 6 (7.3%) 3 (11.5%) 0.372 NO 99 (91.7%) 76 (92.7%) 23 (88.5%) REMOVED LIVER WEIGHT (grams) 450.00 [138.27;707.75] 450.00 [159.27;753.00] 448.55 [123.52;676.50] 0.937 RESECTION MARGIN DISTANCE (mm) 0.10 [0.00;1.00] 0.10 [0.00;1.00] 0.20 ]0.00;1.50] 0.447 Table 2 ( cont ). SURGERY AND PATHOLOGIC RELATED CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID − 2 CATEGORIES [ALL] N = 108 SOS a G 0–1 N = 82 SOS a G 2–3 N = 26 p.overall PATHOLOGICAL TUMOR RESPONSE BY RUBBIA-BRANDT CRITERIA (2 CATEGORIES) TRG b NOT RESPONDERS (TRG 4–5) 47 (43.5%) 37 (45.1%) 10 (38.5%) 0.358 TRG b RESPONDERS (TRG 1–3) 61 (56.5%) 45 (54.9%) 16 (61.5%) a Sinusoidal Obstruction Syndrome b Tumor Regresion Grade Table 3 CLINICAL, PATHOLOGICAL AND SURGERY CHARACTERISTICS BY EARLY PORTAL HYPERTENSION (NO vs YES) [ALL] N = 108 NO N = 85 YES N = 23 p.overall N GENDER : 0.551 108 MEN 67 (62.0%) 51 (60.0%) 16 (69.6%) WOMAN 41 (38.0%) 34 (40.0%) 7 (30.4%) AGE AT LIVER SURGERY 63.0 [56.0;70.2] 64.0 [56.0;71.0] 63.0 [56.0;69.5] 0.615 108 CHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY : 0.283 108 OXALIPLATIN + 5FU 69 (63.9%) 57 (67.1%) 12 (52.2%) IRINOTECAN + 5FU 39 (36.1%) 28 (32.9%) 11 (47.8%) NUMBER OF CHEMOTHERAPY CYCLES BEFORE LIVER SURGERY 7.00 [5.00;11.0] 7.00 [5.00;11.0] 7.00 [6.50;12.0] 0.400 108 CUMULATIVE DOSE OF OXALIPLATIN (mg/m2) 544 [361;833] 518 [361;795] 586 [429;994] 0.590 69 CUMULATIVE DOSE OF IRINOTECAN (mg/m2) 1260 [1076;1791] 1278 [1053;1786] 1260 [1076;1692] 0.913 39 MONOCLONAL ANTIBODY BEFORE LIVER SURGERY : 0.158 108 EGFR INHIBITOR 54 (50.0%) 39 (45.9%) 15 (65.2%) VEGF INHIBITOR 54 (50.0%) 46 (54.1%) 8 (34.8%) NUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY 6.00 [4.00;9.00] 6.00 [4.00;9.00] 7.00 [4.00;10.0] 0.309 108 EMBOLIZATION OR PORTAL LIGATION PRIOR TO LIVER SURGERY : 0.022 108 YES 29 (26.9%) 18 (21.2%) 11 (47.8%) NO 79 (73.1%) 67 (78.8%) 12 (52.2%) HEPATIC CLAMPING TIME (min) 38.0 [18.0;81.0] 35.0 [15.0;73.0] 54.5 [30.0;88.5] 0.054 101 REINTERVENTION : 1.000 108 YES 9 (8.33%) 7 (8.24%) 2 (8.70%) NO 99 (91.7%) 78 (91.8%) 21 (91.3%) PATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA − 2 CATEGORIES : 0.809 108 TRG NOT RESPONDERS (TRG4-5) 47 (43.5%) 38 (44.7%) 9 (39.1%) TRG RESPONDERS (TRG1-3) 61 (56.5%) 47 (55.3%) 14 (60.9%) HEPATOPATHY PRIOR TO LIVER SURGERY : 0.721 101 NONE OR MILD HEPATOPATHY 54 (53.5%) 44 (55.0%) 10 (47.6%) MODERATE OR SEVERE HEPATOPATHY 47 (46.5%) 36 (45.0%) 11 (52.4%) BODY MASS INDEX (kg/m 2 ) 25.08 [22.95;27.04] 25.24 [22.86;27.25] 24.54 [23.83;26.44] 0.834 108 CLINICAL RISC SCORE - FONG − 2 CATEGORIES : 0.197 94 CLINICAL RISK SCORE 0–2 36 (38.3%) 32 (42.1%) 4 (22.2%) CLINICAL RISK SOCRE 3–5 58 (61.7%) 44 (57.9%) 14 (77.8%) SINUSOIDAL OBSTRUCTION SYNDROME (SOS) GRADE : < 0.001 108 SOS G 0–1 82 (75.9%) 73 (85.9%) 9 (39.1%) SOS G 2–3 26 (24.1%) 12 (14.1%) 14 (60.9%) Table 3 ( cont ). CLINICAL, PATHOLOGICAL AND SURGERY CHARACTERISTICS BY EARLY PORTAL HYPERTENSION (NO vs YES) [ALL] N = 108 NO N = 85 YES N = 23 p.overall N CALCULATED PROBABILITY TO SOS G 2–3 0.21 [0.08;0.32] 0.21 [0.08;0.26] 0.30 [0.14;0.49] 0.018 108 Table 4 UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT SINUSOIDAL DAMAGE Univariate analysis Multivariate anaysis [ALL] N = 108 SOS 1 G 0–1 N = 82 SOS 1 G 2–3 N = 26 OR [IC95%] p.overall N [ALL] N = 108 OR [IC95%] p.overall coefficient GENDER : 108 MEN 67 (62.0%) 50 (61.0%) 17 (65.4%) Reference WOMAN 41 (38.0%) 32 (39.0%) 9 (34.6%) 0.83 [0.32;2.08] 0.701 AGE AT LIVER SURGERY (years) 63.0 [56.0;70.2] 63.0 [56.0;70.0] 65.0 [56.2;70.8] 1.00 [0.98;1.01] 0.655 108 CHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY : 108 OXALIPLATIN + 5FU 69 (63.9%) 52 (63.4%) 17 (65.4%) Reference IRINOTECAN + 5FU 39 (36.1%) 30 (36.6%) 9 (34.6%) 0.92 [0.35;2.31] 0.868 NUMBER OF CHEMOTHERAPY CYCLES BEFORE LIVER SURGERY 7.00 [5.00;11.0] 7.00 [5.25;10.0] 7.50 [5.50;12.8] 1.08 [1.00;1.16] 0.056 108 108 1.085 [0.998–1.180] 0.055 0.082 CUMMULATIVE CHEMOTHERAPY DOSE (mg/m2) 819 [472;1264] 780 [471;1260] 1071 [491;1575] 1.00 [1.00;1.00] 0.384 108 CUMULATIVE DOSE OF OXALIPLATIN (mg/m2) 544 [361;833] 541 [377;772] 544 [340;1275] 1.00 [1.00;1.00] 0.043 69 69 0.99 [0.992–1.007] 0.814 (-)0.001 CUMULATIVE DOSE OF IRINOTECAN (mg/m2) 1260 [1076;1791] 1260 [1080;1741] 1440 [1071;1944] 1.00 [1.00;1.00] 0.860 39 MONOCLONAL ANTIBODY BEFORE LIVER SURGERY : 108 EGFR INHIBITOR 54 (50.0%) 34 (41.5%) 20 (76.9%) Reference 54 VEGF INHIBITOR 54 (50.0%) 48 (58.5%) 6 (23.1%) 0.22 [0.07;0.58] 0.002 54 0.214 [0.075–0.610] 0.004 (-)1.540 NUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY 6.00 [4.00;9.00] 6.00 [4.00;8.75] 7.00 [4.00;11.5] 1.06 [0.98;1.15] 0.135 108 EMBOLIZATION OR PORTAL LIGATION BEFORE LIVER SURGERY : 108 NO 79 (73.1%) 64 (78.0%) 15 (57.7%) Reference 79 YES 29 (26.9%) 18 (22.0%) 11 (42.3%) 2.58 [0.99;6.69] 0.052 29 2.819 [1.019–7.796] 0.046 1036 PATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA 2 CATEGORIES : 108 TRG NOT RESPONDERS (TRG4-5) 47 (43.5%) 37 (45.1%) 10 (38.5%) Reference TRG RESPONDERS (TRG1-3) 61 (56.5%) 45 (54.9%) 16 (61.5%) 1.31 [0.53;3.34] 0.563 PATHOLOGICAL RESPONSE BY POULTSIDES CRITERIA : 108 FIBROSIS < 40% 66 (61.1%) 53 (64.6%) 13 (50.0%) Reference FIBROSIS ≥ 40% 42 (38.9%) 29 (35.4%) 13 (50.0%) 1.82 [0.73;4.51] 0.195 HEPATOPATHY PRIOR TO LIVER SURGERY : 101 NONE OR MILD HEPATOPATHY 54 (53.5%) 39 (51.3%) 15 (60.0%) Reference MODERATE OR SEVERE HEPATOPATHY 47 (46.5%) 37 (48.7%) 10 (40.0%) 0.71 [0.27;1.77] 0.463 BODY MASS INDEX (Kg/m 2 ) 25.08 [22.95;27.04] 25.22 [23.34;27,34] 24.67 [22.43;26.59] 1.04 [0.94;1.15] 0.434 108 NECROSIS CATEGORIES : 108 NECROSIS < 40% 77 (71.3%) 57 (69.5%) 20 (76.9%) Reference Table 4 ( cont ). UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT SINUSOIDAL DAMAGE Univariate analysis Multivariate anaysis [ALL] N = 108 SOS † G 0–1 N = 82 SOS G 2–3 N = 26 OR [IC95%] p.overall N [ALL] N = 108 OR [IC95%] p.overall coefficient NECROSIS ≥ 40% 31 (28.7%) 25 (30.5%) 6 (23.1%) 0.70 [0.23;1.88] 0.486 CLINICAL RISC SCORE - FONG − 2 CATEGORIES : 94 CLINICAL RISK SCORE 0–2 36 (38.3%) 29 (39.7%) 7 (33.3%) Reference CLINICAL RISK SOCRE 3–5 58 (61.7%) 44 (60.3%) 14 (66.7%) 1.30 [0.47;3.86] 0.613 1 Sinusoidal Obstruction Syndrome Multivariate model constant = -1.621 Multivariate model Formula: log (P/1-P) = -1.621 + (0.082 x Num cycles QT) + (-1.540 x AcMO, antiEGFR = 0 or antiVEGF = 1) + (1.036 x Embolization, NO = 0, YES = 1). P = 1 / 1 + e(-1 x ((-1.621 + (0.082 x Num cycles QT) + (-1.540 x AcMO, antiEGFR = 0 or antiVEGF = 1) + (1.036 x Embolization, NO = 0, YES = 1))). Table 5 UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT EARLY CLINICAL PORTAL HYPERTENSION (HTP) Univariate analysis Multivariate analysis [ALL] N = 108 NO N = 85 YES N = 23 OR [ICO95%] p.overall N [ALL] N = 108 OR [IC95%] p.overall coefficient GENDER : 108 MEN 67 (62.0%) 51 (60.0%) 16 (69.6%) Reference WOMAN 41 (38.0%) 34 (40.0%) 7 (30.4%) 0.67 [0.23;1.75] 0.418 AGE AT LIVER SURGERY 63.0 [56.0;70.2] 64.0 [56.0;71.0] 63.0 [56.0;69.5] 0.99 [0.97;1.02] 0.605 108 CHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY : 108 OXALIPLATIN + 5FU 69 (63.9%) 57 (67.1%) 12 (52.2%) Reference IRINOTECAN + 5FU 39 (36.1%) 28 (32.9%) 11 (47.8%) 1.86 [0.71;4.81] 0.202 NUMBER OF CHEMOTHERAPY CYCLES BEFORE LIVER SURGERY 7.00 [5.00;11.0] 7.00 [5.00;11.0] 7.00 [6.50;12.0] 1.03 [0.95;1.11] 0.492 108 CUMULATIVE CHEMOTHERAPY DOSE (mg/m2) 819 [472;1264] 765 [434;1260] 1071 [586;1294] 1.00 [1.00;1.00] 0.382 108 CUMULATIVE DOSE OF OXALIPLATIN (mg/m2) 544 [361;833] 518 [361;795] 586 [429;994] 1.00 [1.00;1.00] 0.283 69 CUMULATIVE DOSE OF IRINOTECAN (mg/m2) 1260 [1076;1791] 1278 [1053;1786] 1260 [1076;1692] 1.00 [1.00;1.00] 0.620 39 MONOCLONAL ANTIBODY BEFORE LIVER SURGERY : 108 EGFR INHIBITOR 54 (50.0%) 39 (45.9%) 15 (65.2%) Reference VEGF INHIBITOR 54 (50.0%) 46 (54.1%) 8 (34.8%) 0.46 [0.17;1.18] 0.108 NUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY 6.00 [4.00;9.00] 6.00 [4.00;9.00] 7.00 [4.00;10.0] 1.05 [0.96;1.14] 0.294 108 EMBOLIZATION OR PORTAL LIGATION PRIOR TO LIVER SURGERY : 108 YES 29 (26.9%) 18 (21.2%) 11 (47.8%) Reference NO 79 (73.1%) 67 (78.8%) 12 (52.2%) 0.30 [0.11;0.80] 0.016 TYPES OF LIVER SURGERY- 2 CATEGORIES : 108 MINOR HEPATECTOMY 57 (52.8%) 53 (62.4%) 4 (17.4%) Reference 57 MAJOR HEPATECTOMY 51 (47.2%) 32 (37.6%) 19 (82.6%) 7.52 [2.53;28.6] < 0.001 51 7.78 [2.32;25.99] < 0.001 2.052 HEPATIC CLAMPING TIME (min) 38.0 [18.0;81.0] 35.0 [15.0;73.0] 54.5 [30.0;88.5] 1.01 [1.00;1.02] 0.225 101 REINTERVENTION : 108 YES 9 (8.33%) 7 (8.24%) 2 (8.70%) Reference NO 99 (91.7%) 78 (91.8%) 21 (91.3%) 0.90 [0.19;7.05] 0.904 PATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA − 2 CATEGORIES : 108 TRG NOT RESPONDERS (TRG4-5) 47 (43.5%) 38 (44.7%) 9 (39.1%) Reference TRG RESPONDERS (TRG1-3) 61 (56.5%) 47 (55.3%) 14 (60.9%) 1.25 [0.49;3.33] 0.645 PATHOLOGICAL RESPONSE BY POULTSIDES CRITERIA : 108 FIBROSIS < 40% 66 (61.1%) 51 (60.0%) 15 (65.2%) Reference FIBROSIS ≥ 40% 42 (38.9%) 34 (40.0%) 8 (34.8%) 0.81 [0.29;2.09] 0.664 Table 5 ( cont ). UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT EARLY CLINICAL PORTAL HYPERTENSION (HTP) Univariate analysis Multivariate analysis [ALL] N = 108 NO N = 85 YES N = 23 OR [ICO95%] p.overall N [ALL] N = 108 OR [IC95%] p.overall coefficient HEPATOPATHY PRIOR TO LIVER SURGERY : 101 NONE OR MILD HEPATOPATHY 54 (53.5%) 44 (55.0%) 10 (47.6%) Reference MODERATE OR SEVERE HEPATOPATHY 47 (46.5%) 36 (45.0%) 11 (52.4%) 1.34 [0.50;3.60] 0.557 BMI 1 CATEGORIES : 25.28 [22.95;27.04] 25.24 [22.86;27.25] 24.54 [23.83;26.44] 1.04 [0.93;1.15] 0.451 108 NECROSIS CATEGORIES : 108 NECROSIS < 40% 77 (71.3%) 61 (71.8%) 16 (69.6%) Reference NECROSIS ≥ 40% 31 (28.7%) 24 (28.2%) 7 (30.4%) 1.12 [0.38;3.02] 0.827 CLINICAL RISC SCORE - FONG − 2 CATEGORIES : 94 CLINICAL RISK SCORE 0–2 36 (38.3%) 32 (42.1%) 4 (22.2%) Reference CLINICAL RISK SOCRE 3–5 58 (61.7%) 44 (57.9%) 14 (77.8%) 2.46 [0.79;9.64] 0.126 PROBABILITY TO SOS 2 G 2–3 0.21 [0.08;0.32] 0.21 [0.08;0.26] 0.30 [0.14;0.49] 44.30 [3.44;570.33] 0.004 108 108 40.82 [2.60;640.53] 0.008 3.709 1 Body Mass Index , 2 Sinusoidal Obstruction Syndrome Multivariate model constant = -3.585 Multivariate model Formula: log (P/1-P) = -3.585 + (2.052 x Types liver surgery; Minor hepatectomy = 0 or Major hepatectomy = 1) + (3.709 x Probability to SOS G 2–3) P = 1 / 1 + e(-1 x ((-3.585 + (2.052 x Types liver surgery; Minor hepatectomy = 0 or Major hepatectomy = 1) + (3.709 x Probability to SOS G 2–3))) Additional Declarations No competing interests reported. Supplementary Files FIGURE1SUPPLEMENTARY.xlsx Cite Share Download PDF Status: Under Review Version 1 posted Editorial decision: Revision requested 02 Jan, 2026 Reviews received at journal 25 Dec, 2025 Reviews received at journal 20 Dec, 2025 Reviewers agreed at journal 13 Dec, 2025 Reviewers agreed at journal 08 Dec, 2025 Reviewers agreed at journal 08 Dec, 2025 Reviewers invited by journal 08 Dec, 2025 Submission checks completed at journal 25 Nov, 2025 Editor assigned by journal 25 Nov, 2025 First submitted to journal 24 Nov, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8196994","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":557261333,"identity":"bc7ca544-0fa0-430a-8ce0-70cd0c1b1ddf","order_by":0,"name":"XAVIER HERNANDEZ-YAGÜE","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABFElEQVRIie2RsWrDMBCGLxwoi4JXewh+BRVB6dCHkQhkKm2hS4YMBoOnNl4d2ofwG8ThQJO7F5rBEAgdEwLBU6hJSOigtOlWij44pEEfP/8JwOH4i/j7oxUBFsXu2m5GnacwtVfwoLAfFS7gqMA3iniPzfp+OOumXrkq6sEs9BDpoxrCrRdGViV4Mb3nzCzkOHrNp4/l4mIcs/6VMvAQJPYUz7+RyBnpfPqUUyshJYhfCsVA58auMP9ujXxLekK8+qJsQU9OKE0KYidpUhiHgyIrnTQpJ+oHWV9iZ0QyK5loutCuC+iRrzOj7Bt7682Rb6ibpjRf1gMKvXZMq3pzrdO4sMfYCx7/61xw+bv3DofD8c/5BEjhYuGa+LPXAAAAAElFTkSuQmCC","orcid":"","institution":"Institut Català d'Oncologia","correspondingAuthor":true,"prefix":"","firstName":"XAVIER","middleName":"","lastName":"HERNANDEZ-YAGÜE","suffix":""},{"id":557261334,"identity":"7a39e42f-ec7a-4aab-b2a1-45909d370f53","order_by":1,"name":"SANTIAGO LÓPEZ-BEN","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"SANTIAGO","middleName":"","lastName":"LÓPEZ-BEN","suffix":""},{"id":557261335,"identity":"d11e4ee2-926e-4542-a764-e020dd6268fa","order_by":2,"name":"ANA AULA-OLIVAR","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"ANA","middleName":"","lastName":"AULA-OLIVAR","suffix":""},{"id":557261336,"identity":"a70aa1cd-b557-4330-ba06-075b9000fee8","order_by":3,"name":"WALTER CARBAJAL-OCHOA","email":"","orcid":"","institution":"Institut Català d'Oncologia","correspondingAuthor":false,"prefix":"","firstName":"WALTER","middleName":"","lastName":"CARBAJAL-OCHOA","suffix":""},{"id":557261337,"identity":"e016d71e-0e55-46ed-8b85-a0b46759b560","order_by":4,"name":"JOAN MARTÍNEZ-SANCHO","email":"","orcid":"","institution":"Institut d'Investigació Biomèdica de Girona","correspondingAuthor":false,"prefix":"","firstName":"JOAN","middleName":"","lastName":"MARTÍNEZ-SANCHO","suffix":""},{"id":557261338,"identity":"7fa83195-cfcc-4684-9a6b-5227019c92ca","order_by":5,"name":"MARIA TERESA ALBIOL-QUER","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"MARIA","middleName":"TERESA","lastName":"ALBIOL-QUER","suffix":""},{"id":557261339,"identity":"8d55d7f3-b7f4-4eff-8bef-28049bcf9f86","order_by":6,"name":"GEMMA OSCA-GELIS","email":"","orcid":"","institution":"Institut Català d'Oncologia","correspondingAuthor":false,"prefix":"","firstName":"GEMMA","middleName":"","lastName":"OSCA-GELIS","suffix":""},{"id":557261340,"identity":"47aa7ee0-c1e9-4a87-81a0-d2288d63ef22","order_by":7,"name":"MARIA ROSA ORTÍZ-DURAN","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"MARIA","middleName":"ROSA","lastName":"ORTÍZ-DURAN","suffix":""},{"id":557261341,"identity":"181f9612-e1f5-4228-94e7-f1961f252085","order_by":8,"name":"LAIA FALGUERAS-VERDAGUER","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"LAIA","middleName":"","lastName":"FALGUERAS-VERDAGUER","suffix":""},{"id":557261342,"identity":"94c80987-80e6-477a-8138-77975eae5f73","order_by":9,"name":"MARIA BUXÓ-PUJOLRÀS","email":"","orcid":"","institution":"Institut d'Investigació Biomèdica de Girona","correspondingAuthor":false,"prefix":"","firstName":"MARIA","middleName":"","lastName":"BUXÓ-PUJOLRÀS","suffix":""},{"id":557261343,"identity":"93fff12c-fed6-40eb-96f4-e352319d1ff3","order_by":10,"name":"CRISTINA MELÉNDEZ-MUÑOZ","email":"","orcid":"","institution":"Hospital Universitari de Girona Doctor Josep Trueta","correspondingAuthor":false,"prefix":"","firstName":"CRISTINA","middleName":"","lastName":"MELÉNDEZ-MUÑOZ","suffix":""},{"id":557261344,"identity":"e207386a-333e-425b-bd0c-74172538d981","order_by":11,"name":"JOAN FIGUERAS I FELIP","email":"","orcid":"","institution":"University of Girona","correspondingAuthor":false,"prefix":"","firstName":"JOAN","middleName":"FIGUERAS I","lastName":"FELIP","suffix":""}],"badges":[],"createdAt":"2025-11-24 21:38:10","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8196994/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8196994/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":97932749,"identity":"79e51adb-fc0c-4186-bbb9-87cfefe89e2f","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":307714,"visible":true,"origin":"","legend":"","description":"","filename":"ARTICLEXHERNANDEZYAGUEInternationalJournalofColorectalDisease.docx","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/65fe4c90993a265c2dcb442e.docx"},{"id":98422989,"identity":"48bd4279-7a6e-45b0-a965-fe3baf8bf07f","added_by":"auto","created_at":"2025-12-17 16:31:43","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":12680,"visible":true,"origin":"","legend":"","description":"","filename":"dfedb7924e634cd688c538e8f6921e28.json","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/566ccea49f9c0a939e494e10.json"},{"id":97932753,"identity":"6e47c70e-cf81-4d97-a25a-d19fc5781348","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"xlsx","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":11153,"visible":true,"origin":"","legend":"","description":"","filename":"FIGURE1SUPPLEMENTARY.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/1d920cc270ba977bc47047c5.xlsx"},{"id":98421543,"identity":"c6f25c4d-4ea4-4916-98d2-c92d064a7790","added_by":"auto","created_at":"2025-12-17 16:28:24","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":208710,"visible":true,"origin":"","legend":"","description":"","filename":"dfedb7924e634cd688c538e8f6921e281enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/2dbf7674fe4024cbb14441a0.xml"},{"id":98423042,"identity":"f40f9efd-c538-4764-bfd5-9420a24fa108","added_by":"auto","created_at":"2025-12-17 16:31:46","extension":"jpeg","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":1074,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/9e2297066929221ee7a4a37f.jpeg"},{"id":97932756,"identity":"005ea25e-44cf-40d2-9427-8239abfa54cc","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":39141,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/86cad0e6dc6b54e84237da0a.jpeg"},{"id":97932759,"identity":"c884e712-3a94-44c4-a8d3-b46d2d5a0154","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":27503,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/fcde0e94b1f60c8c75487b92.png"},{"id":98422377,"identity":"39fc0f79-d4fe-4c91-b7a6-9e938bc91db7","added_by":"auto","created_at":"2025-12-17 16:30:56","extension":"jpeg","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":19876,"visible":true,"origin":"","legend":"","description":"","filename":"groupimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/a89c0480e5026231a6b24f43.jpeg"},{"id":98421883,"identity":"ac164050-f152-4918-9699-3445eba0f333","added_by":"auto","created_at":"2025-12-17 16:29:52","extension":"jpeg","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":17811,"visible":true,"origin":"","legend":"","description":"","filename":"groupimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/1e54bc280bbe40ff6970095b.jpeg"},{"id":98422589,"identity":"7b663695-8c89-456e-af6f-0326a0c3ab8b","added_by":"auto","created_at":"2025-12-17 16:31:14","extension":"png","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":935,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/a2da630689720f2a79c5a1ff.png"},{"id":97932751,"identity":"5922a278-2d69-4698-850d-80ca0fe23859","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"png","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":14018,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/6311111bd679cb0cf5e38baa.png"},{"id":97932763,"identity":"74708fde-24d1-4aa4-9ba6-c71929fbe1f7","added_by":"auto","created_at":"2025-12-11 00:46:04","extension":"png","order_by":11,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":14806,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/e66193846c72d8353b1b2a22.png"},{"id":97932758,"identity":"1eaf910a-90a9-4cd3-91dc-897f7fa4641c","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"png","order_by":12,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":6892,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinegroupimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/c838920102a0481e5c063438.png"},{"id":98421737,"identity":"f32d317e-afab-4054-91f9-b57577475f61","added_by":"auto","created_at":"2025-12-17 16:29:11","extension":"png","order_by":13,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":6784,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinegroupimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/e57085ca1751f32d3369b114.png"},{"id":97932761,"identity":"58d1fca9-a480-4e1c-bf96-3c14ca85e2db","added_by":"auto","created_at":"2025-12-11 00:46:04","extension":"xml","order_by":14,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":212200,"visible":true,"origin":"","legend":"","description":"","filename":"dfedb7924e634cd688c538e8f6921e281structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/8403da8a17b00a2fee786ffc.xml"},{"id":98421578,"identity":"51e9facc-6252-4a62-848c-fe88a1e5470c","added_by":"auto","created_at":"2025-12-17 16:28:35","extension":"html","order_by":15,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":226213,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/9c185d4f3ad15ffaea05972a.html"},{"id":97932746,"identity":"c683310f-5819-447d-9021-aa2cea1526b7","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":117401,"visible":true,"origin":"","legend":"\u003cp\u003ePredictive models for SOS G2-3 (Sinusoidal Obstruction Syndrome) and ePHT (early Portal Hypertension). Area Under Curve (AUC).\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/c89157be28c800e62a6f7906.png"},{"id":97932745,"identity":"1c6320aa-c573-4b08-96e7-447604d74fe0","added_by":"auto","created_at":"2025-12-11 00:46:03","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":187281,"visible":true,"origin":"","legend":"\u003cp\u003eOverall survival according Sinusoidal Obstruction Syndrome (SOS) or Early Portal Hypertension (ePHT).\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/6ec7e69ba9e2c6e72bc3eb94.png"},{"id":98622004,"identity":"e5eb3c75-522f-421e-aaf0-c1e67b987129","added_by":"auto","created_at":"2025-12-19 16:40:05","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":3360411,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/e9c0a0a5-81d5-4cfa-8a4b-c5f0de762691.pdf"},{"id":98421577,"identity":"6cb7e126-1c5d-48eb-bdc6-0f6ce7efcc3f","added_by":"auto","created_at":"2025-12-17 16:28:35","extension":"xlsx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":11153,"visible":true,"origin":"","legend":"","description":"","filename":"FIGURE1SUPPLEMENTARY.xlsx","url":"https://assets-eu.researchsquare.com/files/rs-8196994/v1/887a377e38d5c052e43c2262.xlsx"}],"financialInterests":"No competing interests reported.","formattedTitle":"\u003cp\u003eSinusoidal Injury and Portal Hypertension after Hepatectomy for Colorectal Liver Metastases: Predictors, Risk Stratification, and Clinical Outcomes\u003c/p\u003e","fulltext":[{"header":"INTRODUCTION","content":"\u003cp\u003eLiver resection for colorectal cancer liver metastases (CRLM) after neoadjuvant chemotherapy is an established curative strategy. While the short-term toxicities of systemic therapy are well described, its long-term hepatic consequences among cancer survivors remain poorly characterized.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe liver is the predominant site of metastasis in metastatic colorectal cancer (mCRC), and resection remains the only potentially curative treatment(1). Patients with resectable or borderline-resectable CRLM often receive intensive conversion chemotherapy to achieve operability (2\u0026ndash;4). However, in the pursuit of resectability, the deleterious hepatic effects of chemotherapy\u0026mdash;both immediate and delayed\u0026mdash;are frequently underestimated.\u003c/p\u003e\n\u003cp\u003eUnderstanding chemotherapy-induced hepatotoxicity is essential to assess perioperative risks (i.e., bleeding, ascites), postoperative outcomes (i.e., portal hypertension, hepatic failure), and long-term surveillance needs. Robinson et al. provided a comprehensive meta-analysis of chemotherapy-related liver injury in resected CRLM (5). Three major histopathological entities can be identified:\u003c/p\u003e\n\u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003e\u003cstrong\u003eHepatic Steatosis\u003c/strong\u003e\u003cbr\u003eCharacterized by intrahepatocellular fat accumulation, steatosis is graded as 0 = absent, 1 = mild (0\u0026ndash;33%), 2 = moderate (33\u0026ndash;66%), and 3 = severe (\u0026gt;66%) (6). Severe steatosis (\u0026gt;30%) triples postoperative mortality after major hepatectomy (\u0026gt;3 segments) (7). However, meta-analyses show no consistent association between chemotherapy for CRLM and severe steatosis (5).\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSteatohepatitis\u003c/strong\u003e\u003cbr\u003eDefined by fatty infiltration with inflammatory changes and hepatocellular ballooning (Brunt EM criteria) (8), steatohepatitis may progress to fibrosis, cirrhosis, and hepatic failure. Risk factors include type 2 diabetes, metabolic syndrome, and obesity (BMI \u0026gt;35 kg/m\u0026sup2;). Ninety-day postoperative mortality is significantly higher in affected patients (OR 10.5; 95% CI 2.0\u0026ndash;36.4; p = 0.001) (9). Irinotecan markedly increases this risk (RR 3.45; 95% CI 1.12\u0026ndash;10.62; p = 0.03), while oxaliplatin does not (RR 1.17; 95% CI 0.45\u0026ndash;3.04; p = 0.75).\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSinusoidal Injury\u003c/strong\u003e\u003cbr\u003eGraded from 0 (absent) to 3 (severe, full-lobular involvement) (10), sinusoidal injury progresses from dilatation and hepatocellular atrophy to perisinusoidal fibrosis and nodular regenerative hyperplasia. Moderate-to-severe injury (grades 2\u0026ndash;3) is not associated with increased postoperative mortality (OR 1.21; 95% CI 0.23\u0026ndash;6.35; p = 0.82) (11). However, oxaliplatin significantly increases the risk, especially after\u0026nbsp;\u0026ge;6 cycles (RR 3.20; 95% CI 1.01\u0026ndash;10.13; p = 0.048) (12). In contrast irinotecan does not appear to increase this risck (5). Bevacizumab co-administration reduces the incidence of sinusoidal injury (HR 0.50; 95% CI 0.37\u0026ndash;0.67; p \u0026lt; 0.00001) but does not significantly lower postoperative hepatic failure (HR 0.61; 95% CI 0.34\u0026ndash;1.07; p = 0.08) (13).\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eAdvanced nonalcoholic steatohepatitis (NASH) with fibrosis increases all-cause mortality proportionally to fibrosis stage (14). Five-year survival may be significantly lower in patients with moderate-to-severe sinusoidal injury (HR 2.52; 95% CI 1.25\u0026ndash;5.50; p = 0.010) (15).\u003c/p\u003e\n\u003cp\u003eGiven these findings, structured long-term surveillance is warranted for patients undergoing hepatic resection for CRLM, most of whom have received perioperative chemotherapy. Preventive strategies\u0026mdash;including metabolic control, weight optimization, and regular hepatic imaging\u0026mdash;should be integrated into multidisciplinary follow-up protocols in collaboration with hepatology specialists. Early detection and treatment of complications (i.e., non-selective beta-blockers, endoscopic ligation) are essential to improve long-term outcomes.\u003c/p\u003e\n\u003cp\u003eThis study analyzes medium- and long-term hepatic complications following chemotherapy for CRLM and discusses their clinical implications for follow-up.\u003c/p\u003e"},{"header":"MATERIALS AND METHODS","content":"\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003eHypothesis and Study Objectives\u003c/h2\u003e\u003cp\u003eThe primary objective was to identify factors associated with the development of hepatic sinusoidal injury (Sinusoidal Obstruction Syndrome, SOS) and the occurrence of early clinical manifestations of portal hypertension (ePHT) (defined as those appearing within the first three monts after hepatic surgery) in patients undergoing liver surgery for colorectal cancer liver metastases (CRLM) following preoperative systemic therapy. The secondary objective was to evaluate the impact of SOS and ePHT on overall survival (OS), providing the rationale for targeted long-term surveillance in this population. Additionally, a risk calculator for predicting SOS or early portal hypertension will be developed in Microsoft Excel format to enable clinical use and facilitate external validation by other research groups. This investigation represents a secondary analysis derived from a previously published study originally powered to assess pathological tumor response\u0026mdash;specifically, the degree of chemotherapy-induced fibrosis\u0026mdash;in patients treated with epidermal growth factor receptor (anti-EGFR) versus vascular endothelial growth factor (anti-VEGF) inhibitor\u0026ndash;based regimens(\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e).\u003c/p\u003e\u003c/div\u003e\n\u003ch3\u003eStudy Design and Population\u003c/h3\u003e\n\u003cp\u003eThis retrospective, registry-based study included patients who underwent hepatic resection for CRLM after at least four cycles of preoperative chemotherapy combined with targeted therapy (anti-Epidermal Growth Factor Receptor (anti-EGFR) or anti-Vascular Endotelial Growth Factor (anti-VEGF)) at the Hospital Universitari de Girona Dr. Josep Trueta. The study was approved by the institutional ethics committee (code: 2019.130) and conducted in accordance with the Declaration of Helsinki. All surviving patients gave written informed consent for participation in the study.\u003c/p\u003e\u003cp\u003e\u003cb\u003eInclusion criteria\u003c/b\u003e were: 1. Histologically confirmed colorectal adenocarcinoma, 2. Liver metastases deemed resectable or potentially resectable by a multidisciplinary tumor board (MDT), 3. Receipt of \u0026ge;\u0026thinsp;4 cycles of neoadjuvant chemotherapy plus anti-EGFR or anti-VEGF therapy, 4. R0 liver resection (complete macroscopic and microscopic clearance), regardless of concurrent resection of extrahepatic disease.\u003c/p\u003e\u003cp\u003eBased on these criteria, 108 patients were included in the final analysis. For the primary endpoint, all patients underwent thoracoabdominal computed tomography and complete blood count at 3 months post-hepatectomy.\u003c/p\u003e\u003cp\u003e\u003cb\u003eExclusion criteria\u003c/b\u003e were: 1. Preoperative platelet count\u0026thinsp;\u0026lt;\u0026thinsp;100 \u0026times; 10⁹/L, 2. Preoperative splenomegaly\u0026thinsp;\u0026gt;\u0026thinsp;12 cm on CT scan, 3. Radiologic or clinical evidence of ascites or esophagogastric varices before surgery.\u003c/p\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003eDefinitions and Clinical Criteria\u003c/h2\u003e\u003cp\u003e\u003cb\u003eEarly portal hypertension (ePHT)\u003c/b\u003e was defined as the presence of any of the following within 3 months after liver resection: platelet count\u0026thinsp;\u0026lt;\u0026thinsp;100 \u0026times; 10⁹/L, radiological or clinical esophagogastric varices, splenomegaly\u0026thinsp;\u0026gt;\u0026thinsp;12 cm (maximum diameter on CT), or radiological/clinical ascites.\u003c/p\u003e\u003cp\u003e\u003cb\u003ePreoperative hepatopathy\u003c/b\u003e was graded as follows: 0\u0026thinsp;=\u0026thinsp;none (no history of liver disease), 1\u0026thinsp;=\u0026thinsp;mild (abnormal liver enzymes, negative viral serology, no imaging evidence of chronic disease), 2\u0026thinsp;=\u0026thinsp;moderate (abnormal enzymes\u0026thinsp;\u0026plusmn;\u0026thinsp;viral positivity, imaging or clinical evidence of chronic disease without cirrhosis), 3\u0026thinsp;=\u0026thinsp;severe (liver cirrhosis of any etiology, Child\u0026ndash;Pugh A).\u003c/p\u003e\u003cp\u003e\u003cb\u003eClinical Risk Score (CRS)\u003c/b\u003e was calculated according to Fong \u003cem\u003eet al.\u003c/em\u003e and categorized as low (0\u0026ndash;2) or intermediate/high (\u003cspan additionalcitationids=\"CR4\" citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e)(\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e).\u003c/p\u003e\u003cp\u003e\u003cb\u003eLymph Node Ratio (LNR)\u003c/b\u003e was defined as the ratio of positive regional lymph nodes to the total number retrieved in the colectomy or rectal resection specimen.\u003c/p\u003e\u003cp\u003e\u003cb\u003eLiver failure\u003c/b\u003e was defined according to the International Study Group of Liver Surgery (ISGLS) and categorized as NO or YES (Grades A, B or C)(\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e).\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec9\" class=\"Section2\"\u003e\u003ch2\u003eStatistical Analysis\u003c/h2\u003e\u003cp\u003e\u003cstrong\u003eSample size\u003c/strong\u003e\u003cp\u003eThe original study design was powered to detect a difference in the proportion of patients achieving\u0026thinsp;\u0026ge;\u0026thinsp;40% tumor fibrosis between EGFR inhibitor\u0026ndash; and VEGF inhibitor\u0026ndash;based regimens. Based on this endpoint, 52 patients per group (total N\u0026thinsp;=\u0026thinsp;104) were required for adequate power(\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e). The current analysis, focusing on SOS and ePHT, was exploratory and hypothesis-generating.\u003c/p\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eStatistical methods\u003c/strong\u003e\u003cp\u003eCategorical variables were summarized as absolute frequencies and percentages, and compared using the Chi-square or Fisher\u0026rsquo;s exact test, as appropriate. Continuous variables were expressed as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation (SD) or median and interquartile range (IQR), depending on data distribution.\u003c/p\u003e\u003c/p\u003e\u003cp\u003eNormality was assessed using the Shapiro\u0026ndash;Wilk test. Parametric data were analyzed using Student\u0026rsquo;s \u003cem\u003et\u003c/em\u003e test (two groups) or ANOVA (multiple groups); nonparametric data were analyzed using the Mann\u0026ndash;Whitney \u003cem\u003eU\u003c/em\u003e or Kruskal\u0026ndash;Wallis test.\u003c/p\u003e\u003cp\u003eBinary logistic regression models were constructed to identify factors associated with moderate-to-severe SOS (grade 2\u0026ndash;3) or ePHT. Variables with \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026le;\u0026thinsp;0.10 in univariate analysis and those deemed clinically relevant were entered into multivariate models. Predictive performance was evaluated using Receiver Operating Characteristic (ROC) curves and calculation of the Area Under the Curve (AUC).\u003c/p\u003e\u003cp\u003eUsing the risk and protective coefficients of the variables included in the multivariate model for grade 2\u0026ndash;3 sinusoidal obstruction syndrome (SOS), the individual probability of developing SOS G2\u0026ndash;3 was calculated for each patient. This derived variable, termed \u003cem\u003eCalculated Probability to SOS G2\u0026ndash;3\u003c/em\u003e), was subsequently incorporated as a preoperative informative variable into the early portal hypertension (ePHT) risk prediction model.\u003c/p\u003e\u003cp\u003eTo prevent multicollinearity, the covariates used in the derivation of the \u003cem\u003eCalculated Probability to SOS G2\u0026ndash;3\u003c/em\u003e were excluded from the multivariate logistic regression model evaluating independent predictors of early portal hypertension (ePHT).\u003c/p\u003e\u003cp\u003eOverall survival was analyzed using Kaplan\u0026ndash;Meier estimates and compared using the log-rank test. A two-tailed \u003cem\u003ep\u003c/em\u003e value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant. All analyses were performed using SPSS (IBM Corp., Armonk, NY) and R statistical software.\u003c/p\u003e\u003c/div\u003e"},{"header":"RESULTS","content":"\u003cp\u003e\u003cb\u003e1. Descriptives\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003e1.1 Clinical and Treatment-Related Characteristics by Sinusoidal Obstruction Syndrome Severity (Grades 0\u0026ndash;1 vs. 2\u0026ndash;3) (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eA total of 108 patients with colorectal liver metastases (CRLM) who underwent hepatic resection were included from September 2005 to January 2023. The median age was 63 years [IQR 56\u0026ndash;70] and the median body mass index (BMI) was 25.1 kg/m\u0026sup2; [IQR 22.9\u0026ndash;27.0], with no significant differences between groups. No significant differences were observed between groups regarding primary tumor location, metastasis distribution, timing of metastasis, preoperative hepatopathy, lymph node ratio, or the type and cumulative dose of systemic chemotherapy.\u003c/p\u003e\u003cp\u003eRAS/BRAF mutations were identified in 39.4% of patients, showing a trend toward lower prevalence in those with higher-grade sinusoidal obstruction (26.9% vs. 43.6%), although this difference did not reach statistical significance (p\u0026thinsp;=\u0026thinsp;0.100).\u003c/p\u003e\u003cp\u003eIn contrast, the use of targeted agents demonstrated significant differences: anti-VEGF were significantly less frequent among patients with high-grade sinusoidal obstruction (23.1% vs. 58.5%) (p\u0026thinsp;=\u0026thinsp;0.001). The number of monoclonal antibody cycles did not differ significantly between groups (p\u0026thinsp;=\u0026thinsp;0.406).\u003c/p\u003e\u003cp\u003eAccording to the Fong Clinical Risk Score, 61.7% of patients were classified as high-risk (score 3\u0026ndash;5) and 38.3% as low-risk (score 0\u0026ndash;2), with no significant difference between groups (p\u0026thinsp;=\u0026thinsp;0.395).\u003c/p\u003e\u003cp\u003e\u003cb\u003e1.2 Surgical and Pathological Outcomes by Sinusoidal Obstruction Syndrome Severity (Grades 0\u0026ndash;1 vs. 2\u0026ndash;3) (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003ePreoperative portal vein embolization (PVE) or ligation emerged as the only factor significantly associated with the development of moderate-to-severe SOS (42.3% vs. 22.0%, p\u0026thinsp;=\u0026thinsp;0.040).\u003c/p\u003e\u003cp\u003eIn contrast, no other clinical, operative, or pathological variables demonstrated a significant relationship with SOS severity. Neither patient demographics, tumor characteristics, nor the timing of metastasis showed meaningful differences between groups.\u003c/p\u003e\u003cp\u003ePostoperative outcomes did not differ significantly by SOS status. Rates of biliary fistula (8.3%), hemoperitoneum (11.1%), ascites (13.9%), and post-hepatectomy liver failure (13.9%) were comparable (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Major complications (Dindo\u0026ndash;Clavien grades 3\u0026ndash;5)(\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e) occurred in 25.9% of patients, and the 90-day mortality rate was 8.3%, with no significant group differences (p\u0026thinsp;=\u0026thinsp;0.182 and 0.372, respectively).\u003c/p\u003e\u003cp\u003e\u003cb\u003e1.3 Clinical and Treatment-Related Characteristics by Early Portal Hypertension (NO vs. YES).\u003c/b\u003e Table\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e\u003c/p\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e summarizes the clinical, pathological, and treatment-related characteristics of the 108 patients included in the study, stratified according to the development of early clinical portal hypertension (ePHT), which occurred in 21.3% of cases (n\u0026thinsp;=\u0026thinsp;23).\u003c/p\u003e\u003cp\u003eBaseline demographic and clinical variables, including sex distribution, age at surgery, body mass index, baseline hepatopathy, and Fong Clinical Risk Score, were comparable between groups (all p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Similarly, the type of chemotherapy backbone (oxaliplatin- vs. irinotecan-based), the number of cycles, and cumulative drug doses showed no significant association with the development of ePHT.\u003c/p\u003e\u003cp\u003eAmong perioperative factors, preoperative portal vein embolization or ligation was significantly more frequent in patients who developed ePHT (47.8% vs. 21.2%, p\u0026thinsp;=\u0026thinsp;0.022). Hepatic inflow occlusion time (clamping time) showed a non-significant trend toward longer duration in the ePHT group (median 54.5 vs. 35.0 minutes, p\u0026thinsp;=\u0026thinsp;0.054).\u003c/p\u003e\u003cp\u003eWith respect to targeted therapy, patients who developed ePHT more frequently received less frequently anti-VEGF inhibitors (34.8% vs. 54.1%), though these differences did not reach statistical significance (p\u0026thinsp;=\u0026thinsp;0.158). Reintervention rates, pathological tumor response, and other postoperative parameters were likewise similar across groups.\u003c/p\u003e\u003cp\u003eHistopathological assessment revealed a significantly higher proportion of grade 2\u0026ndash;3 sinusoidal obstruction syndrome (SOS) among patients with ePHT (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Based on its strong statistical association and potential preoperative predictive value, a derived variable\u0026mdash;\u003cem\u003eCalculated Probability to SOS G2\u0026ndash;3\u003c/em\u003e\u0026mdash;was generated from the multivariate SOS prediction model. This variable also differed significantly between ePHT groups (ePHT\u0026thinsp;=\u0026thinsp;YES: median risk\u0026thinsp;=\u0026thinsp;0.30 [0.14\u0026ndash;0.49] vs ePHT\u0026thinsp;=\u0026thinsp;NO: median risk\u0026thinsp;=\u0026thinsp;0.21 [0.08\u0026ndash;0.26], p\u0026thinsp;=\u0026thinsp;0.018) and was included in the logistic regression model for early portal hypertension prediction.\u003c/p\u003e\u003cp\u003e\u003cb\u003e3. Predictive Model for Sinusoidal Obstruction Syndrome (SOS)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eA logistic regression analysis was performed to identify clinical and therapeutic factors associated with the development of moderate-to-severe sinusoidal obstruction syndrome (SOS grades 2\u0026ndash;3) following hepatic resection in patients previously treated with neoadjuvant chemotherapy.\u003c/p\u003e\u003cp\u003e\u003cb\u003e3.1 Univariate Analysis (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eIn univariate analysis, no significant association was observed between the occurrence of SOS G2\u0026ndash;3 and sex, age at surgery, or chemotherapy backbone (oxaliplatin- vs. irinotecan-based), all p\u0026thinsp;\u0026gt;\u0026thinsp;0.05. The number of chemotherapy cycles showed a trend toward increased risk of sinusoidal injury with each additional cycle (OR\u0026thinsp;=\u0026thinsp;1.08; 95% CI: 1.00\u0026ndash;1.16; p\u0026thinsp;=\u0026thinsp;0.056). The cumulative oxaliplatin dose was associated with the presence of SOS G2\u0026ndash;3 (p\u0026thinsp;=\u0026thinsp;0.043). The use of anti-VEGF therapy before liver surgery was significantly associated with a lower risk of SOS G2\u0026ndash;3 compared with anti-EGFR therapy (OR\u0026thinsp;=\u0026thinsp;0.22; 95% CI: 0.07\u0026ndash;0.58; p\u0026thinsp;=\u0026thinsp;0.002). Conversely, portal vein embolization or ligation tended to increase the risk of SOS (OR\u0026thinsp;=\u0026thinsp;2.58; 95% CI: 0.99\u0026ndash;6.69; p\u0026thinsp;=\u0026thinsp;0.052). No significant associations were found for pathological tumor response (Rubbia\u0026ndash;Brandt or Poulsides criteria(\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e)), baseline hepatopathy, body mass index, extent of necrosis, or Fong Clinical Risk Score (all p\u0026thinsp;\u0026gt;\u0026thinsp;0.05).\u003c/p\u003e\u003cp\u003e\u003cb\u003e3.2 Multivariate Analysis (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eIndependent predictors of moderate-to-severe SOS were identified as follows: Use of anti-VEGF therapy (protective factor): OR\u0026thinsp;=\u0026thinsp;0.214; 95% CI: 0.075\u0026ndash;0.610; p\u0026thinsp;=\u0026thinsp;0.004, Portal vein embolization or ligation (risk factor): OR\u0026thinsp;=\u0026thinsp;2.819; 95% CI: 1.019\u0026ndash;7.796; p\u0026thinsp;=\u0026thinsp;0.046 and Number of chemotherapy cycles (trend, not statistically significant): OR\u0026thinsp;=\u0026thinsp;1.085; 95% CI: 0.998\u0026ndash;1.180; p\u0026thinsp;=\u0026thinsp;0.055. The cumulative oxaliplatin dose did not demonstrate predictive value in the multivariate model for grade 2\u0026ndash;3 sinusoidal obstruction syndrome (SOS) (OR\u0026thinsp;=\u0026thinsp;0.99, 95% CI 0.992\u0026ndash;1.007, p\u0026thinsp;=\u0026thinsp;0.814).\u003c/p\u003e\u003cp\u003eThis predictive algorithm for moderate-to-severe sinusoidal obstruction demonstrated a sensitivity of 75% (n\u0026thinsp;=\u0026thinsp;6/8), a specificity of 80% (n\u0026thinsp;=\u0026thinsp;80/100), and an AUC of 0.750 (95% CI: 0.627\u0026ndash;0.874; standard error (SE)\u0026thinsp;=\u0026thinsp;0.062) on the ROC curve (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e-A).\u003c/p\u003e\u003cp\u003e\u003cb\u003e4. Predictive Model for Early Clinical Portal Hypertension (ePHT)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eA logistic regression analysis was performed to identify factors associated with the development of early clinical portal hypertension (ePHT) after hepatic resection in patients who had received neoadjuvant chemotherapy.\u003c/p\u003e\u003cp\u003e\u003cb\u003e4.1 Univariate Analysis (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eIn univariate analysis, neither sex (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.418) nor age at liver surgery (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.605) was significantly associated with ePHT. No significant associations were observed for chemotherapy regimen (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.202), cumulative chemotherapy dose (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.382), or monoclonal antibody type (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.108). Portal vein embolization or ligation was more frequent among patients who developed ePHT (OR\u0026thinsp;=\u0026thinsp;0.30; 95% CI: 0.11\u0026ndash;0.80; p\u0026thinsp;=\u0026thinsp;0.016). Major hepatectomy showed a strong association with ePHT (OR\u0026thinsp;=\u0026thinsp;7.52; 95% CI: 2.53\u0026ndash;28.6; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Longer hepatic clamping time showed a nonsignificant trend toward increased risk (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.225). Histopathological variables\u0026mdash;including fibrosis, tumor necrosis, and pathological tumor response according to Rubbia\u0026ndash;Brandt or Poulsides criteria\u0026mdash;were not associated with ePHT (\u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026gt;\u0026thinsp;0.05). Conversely, the composite variable \u003cem\u003eCalculated Probability to SOS G2\u0026ndash;3\u003c/em\u003e was significantly associated with clinical ePHT (OR\u0026thinsp;=\u0026thinsp;44.3; 95% CI: 3.44\u0026ndash;570.3; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.004).\u003c/p\u003e\u003cp\u003e\u003cb\u003e4.2 Multivariate Analysis (\u003c/b\u003eTable\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003cp\u003eAfter adjusting for potential confounders, two independent predictors remained significantly associated with the occurrence of clinical HTP: Major hepatectomy: OR\u0026thinsp;=\u0026thinsp;7.78; 95% CI: 2.33\u0026ndash;25.99; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.001; and \u003cem\u003eCalculated Probability to SOS G2\u0026ndash;3\u003c/em\u003e: OR\u0026thinsp;=\u0026thinsp;40.82; 95% CI: 2.60\u0026ndash;640.53; \u003cem\u003ep\u003c/em\u003e\u0026thinsp;=\u0026thinsp;0.008.\u003c/p\u003e\u003cp\u003eNo additional clinical, surgical, or pathological variables showed independent associations.\u003c/p\u003e\u003cp\u003eThis predictive model for clinical portal hypertension achieved a sensitivity of 25% (n\u0026thinsp;=\u0026thinsp;4/12), a specificity of 84.3% (n\u0026thinsp;=\u0026thinsp;81/96), and an AUC of 0.796 (95% CI: 0.690\u0026ndash;0.902; SE\u0026thinsp;=\u0026thinsp;0.053) (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e-B).\u003c/p\u003e\u003cp\u003e\u003cb\u003e4. Overall Survival\u003c/b\u003e\u003c/p\u003e\u003cp\u003eThe Kaplan\u0026ndash;Meier analysis of overall survival showed no significant differences between patients with mild or no sinusoidal obstruction (SOS grade 0\u0026ndash;1) and those with moderate to severe sinusoidal obstruction (SOS grade 2\u0026ndash;3). The median overall survival was 29 months (95% CI, 23.31\u0026ndash;34.68) for the SOS 0\u0026ndash;1 group and 28 months (95% CI, 5.37\u0026ndash;50.62) for the SOS 2\u0026ndash;3 group (log-rank p\u0026thinsp;=\u0026thinsp;0.59) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e-A).\u003c/p\u003e\u003cp\u003eSimilarly, overall survival did not differ significantly according to the presence of clinical features of early portal hypertension. The median overall survival was 27 months (95% CI, 23.08\u0026ndash;30.91) among patients without clinical ePHT, compared with 46 months (95% CI, 27.36\u0026ndash;64.63) among those who developed clinical signs of ePHT (log-rank p\u0026thinsp;=\u0026thinsp;0.37) (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e-B).\u003c/p\u003e"},{"header":"DISCUSSION","content":"\u003cp\u003eIn this retrospective study, we evaluated clinical, pathological, and therapeutic factors associated with the development of early clinical portal hypertension (ePHT) after hepatic resection for colorectal liver metastases (CRLM), as well as its relationship with chemotherapy-induced sinusoidal obstruction syndrome (SOS). Although Portal Hypertension is an uncommon but potentially serious postoperative complication, our findings indicate that it primarily results from the combined effect of extensive hepatic resection and pre-existing sinusoidal injury secondary to neoadjuvant chemotherapy exposure.\u003c/p\u003e\u003cp\u003eThe analysis of factors associated with moderate-to-severe SOS identified two main determinants: the use of anti-VEGF therapy, which exerted a protective effect, and preoperative portal vein embolization or ligation, which significantly increased the risk. A higher number of chemotherapy cycles also showed a trend toward greater sinusoidal injury, although without reaching statistical significance. These results are consistent with previous studies describing the multifactorial nature of chemotherapy-induced hepatic vascular injury(\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e) and emphasize the importance of optimizing neoadjuvant regimens to minimize sinusoidal damage prior to surgery. Oxaliplatin-based chemotherapy has long been recognized as a major contributor to sinusoidal injury through endothelial dysfunction and increased sinusoidal resistance(\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e). In our series, cumulative oxaliplatin exposure correlated with SOS in univariate analysis, but this association did not persist in the multivariate model, suggesting that the risk may be modulated by additional factors, particularly the type of biologic agent used. The protective effect observed with VEGF inhibitors aligns with their endothelial-stabilizing, anti-angiogenic mechanism, which may counteract sinusoidal dilatation and congestion(\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e).\u003c/p\u003e\u003cp\u003eMultivariate analysis revealed that the two independent predictors of postoperative ePHT were major hepatectomy and the calculated probability of developing moderate-to-severe SOS. Major hepatectomy increased the risk of Portal Hypertension nearly eightfold, underscoring the hemodynamic consequences of extensive parenchymal loss and reduced hepatic vascular compliance. These findings are consistent with previous reports linking reduced functional remnant liver volume to increased portal pressure following major resection(\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e). The strong association between the predicted probability of SOS grades 2\u0026ndash;3 and the occurrence of ePHT further supports the pathophysiological connection between chemotherapy-induced vascular injury and impaired hepatic microcirculation.\u003c/p\u003e\u003cp\u003eThe predictive model for ePHT showed good overall discrimination (AUC\u0026thinsp;=\u0026thinsp;0.796) and high specificity (84.3%), although sensitivity remained modest (25%), reflecting the relatively low prevalence of ePHT in this cohort (21%). This limitation likely mirrors the multifactorial nature of postoperative portal hypertension, in which mechanical, vascular, and regenerative factors interact. Nonetheless, the model represents a valuable clinical tool for preoperative risk stratification, particularly among patients who receive prolonged or intensive neoadjuvant chemotherapy. To facilitate clinical application, a risk calculator predicting the probability of developing grade 2\u0026ndash;3 SOS and ePHT was generated using the regression coefficients derived from both multivariate logistic models (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003e. supplementary). Given the high specificity of the early portal hypertension predictive model, it can be concluded that the test reliably identifies patients with a low likelihood of developing ePHT. In such patients, exceptional preoperative interventions or intensive postoperative surveillance aimed at detecting and managing portal hypertension in long-term survivors may not be necessary.\u003c/p\u003e\u003cp\u003eIn contrast, for patients with a high predicted probability of ePHT, preoperative strategies to mitigate this risk should be carefully considered. These may include limiting the number of preoperative chemotherapy cycles, encouraging the use of anti-VEGF therapy, avoiding portal vein embolization, or opting for less extensive hepatic resections when feasible. If modification of these risk factors is not possible, these patients should be enrolled in a structured postoperative follow-up program focused on the early detection and prompt management of portal hypertension, should it occur.\u003c/p\u003e\u003cp\u003eIt is also important to note that, given the model\u0026rsquo;s sensitivity of 25%, only about one in four patients is expected to actually develop early stigmata of portal hypertension.\u003c/p\u003e\u003cp\u003eIn this context, it would be essential to prospectively establish and validate a threshold risk value for ePHT development to guide treatment decisions and minimize the risk of early postoperative portal hypertension.\u003c/p\u003e\u003cp\u003eAs reported by the Johns Hopkins University group (Baltimore, MD, USA), 90-day mortality has been proposed as a more reliable indicator of surgery-related mortality following hepatic resection(\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e). In our series, the 90-day mortality rate was 8.3% (Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e), which may appear higher than expected. However, this cohort represented a high-risk population, with 70.4% (n\u0026thinsp;=\u0026thinsp;76) of patients initially deemed technically unresectable due to extensive tumor burden and the anticipated need for major hepatectomy, frequently combined with prior portal vein embolization or ligation. This high level of surgical complexity likely accounts for the relatively elevated postoperative mortality observed.\u003c/p\u003e\u003cp\u003eDespite the association between sinusoidal obstruction syndrome (SOS) and early portal hypertension (ePHT), neither condition significantly influenced postoperative morbidity, 90-day mortality, nor long-term overall survival. These findings are consistent with previous reports indicating that sinusoidal injury, while common, does not necessarily compromise postoperative or oncologic outcomes when perioperative management is optimized(\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e). The absence of survival differences between patients with and without ePHT further suggests that the development of clinical stigmata of portal hypertension does not inherently indicate irreversible hepatic dysfunction or reduced oncologic efficacy.\u003c/p\u003e\u003cp\u003eOur findings also highlight the complex role of preoperative portal vein embolization (PVE), which was associated with both a higher risk of SOS and increased incidence of ePHT in univariate analyses. Although PVE facilitates hypertrophy of the future liver remnant, it may exacerbate portal pressure gradients and sinusoidal stress, particularly in livers previously exposed to cytotoxic chemotherapy. In such patients, the indication for PVE should be carefully considered, and postoperative surveillance for portal hypertension should be intensified.\u003c/p\u003e\u003cp\u003eThis study has several limitations. Its retrospective, single-center design and the relatively small number of patients developing clinical ePHT may have limited the statistical power of the analyses. The diagnosis of portal hypertension was based on clinical and radiological criteria rather than direct hemodynamic measurements, which may underestimate subclinical cases. Moreover, many patients undergoing hepatic resection for CRLM subsequently received adjuvant chemotherapy\u0026mdash;often oxaliplatin-based\u0026mdash;preventing the assessment of late-onset manifestations of portal hypertension. Despite these limitations, the consistent association between SOS and HTP across analyses supports a biologically plausible relationship with clear clinical relevance. Notably, although subsequent systemic or surgical treatments in patients with recurrent hepatic disease were not analyzed, the potential development of late-onset portal hypertension did not appear to negatively influence overall survival in this cohort.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eIn summary, major hepatectomy and moderate-to-severe sinusoidal obstruction syndrome are the principal determinants of clinical early portal hypertension after liver resection in patients with CRLM treated with neoadjuvant chemotherapy. Anti-VEGF therapy appear to confer a protective effect against sinusoidal injury, whereas preoperative PVE may increase the risk of hepatic vascular complications. Importantly, the occurrence of ePHT did not negatively affect long-term survival, suggesting that, with appropriate perioperative management, its impact may be largely reversible. Prospective studies incorporating direct portal pressure measurements are warranted to validate these results and further refine predictive models for postoperative ePHT.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eCompeting Interests:\u003c/h2\u003e\u003cp\u003eThe authors declare no competing interest.\u003c/p\u003e\u003ch2\u003eFUNDING:\u003c/h2\u003e\u003cp\u003eThis research was funded by the Agrupacio de Ci\u0026egrave;ncies M\u0026egrave;diques i de la Salut de Girona Grant.\u003c/p\u003e\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eConceptualization, X.H-Y, S.L-B and J.F i F.; Methodology, X.H-Y, S.L-B, A.A-O, J.M-S, MT. A-Q, M.R.O-D, L.F-V, M.B-P, C.M-M, and J.F i F; Software, J.M-S, M.B-P, G. O-G. and J.F i F.; Validation, X.H-Y, S.L-B, W.C-O, J.M-S, M.R.O-D, M.B-P. and J.F i F.; Formal analysis, X.H-Y, J.M-S, M.R.O-D., G.O-G, M.B-P. and J.F i F.; Investigation, X.H-Y. and J.F i F.; Resources, X.H-Y, S.L-B, A.A-O, J.M-S, MT. A-Q, M.R.O-D, L.F-V, M.B-P, C.M-M, and J.F i F; Data curation, X.H-Y., S.L-B, W.C-O and J.M-S. All authors have reviewed and agreed to the uploaded version of the manuscript.\u003c/p\u003e\u003ch2\u003eData Availability\u003c/h2\u003e\u003cp\u003eThe data supporting the findings of this study can be obtained by contacting the corresponding author upon request.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAdam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F et al (2012) The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. Oncologist [Internet]. ;17(10):1225\u0026ndash;39. Available from: \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003ehttps://academic.oup.com/oncolo/article/17/10/1225/6400912\u003c/span\u003e\u003cspan address=\"https://academic.oup.com/oncolo/article/17/10/1225/6400912\" targettype=\"URL\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eInnominato PF, Cailliez V, Allard MA, Lopez-Ben S, Ferrero A, Marques H et al (2022) Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers (Basel). ;14(17)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFolprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT et al (2010) Articles Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol [Internet] 11:38\u0026ndash;47 Available from: www.thelancet.com/oncology\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T et al (2011) A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22(9):2042\u0026ndash;2048\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRobinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis. 19:4287\u0026ndash;4299Annals of Surgical Oncology\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u0026ndash;1321\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDe Meijer VE, Kalish BT, Puder M, IJzermans JNM (2010) Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 97:1331\u0026ndash;1339\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBrunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR (1999) Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging the Histological Lesions\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065\u0026ndash;2072\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460\u0026ndash;466\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVan Mierlo KMC, Zhao J, Kleijnen J, Rensen SS, Schaap FG, Dejong CHC et al (2016) The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: A systematic review with meta-analysis. Surg Oncol 25(3):298\u0026ndash;307\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247(1):118\u0026ndash;124\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVolk AM, Fritzmann J, Reissfelder C, Weber GF, Weitz J, Rahbari NN (2016) Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases. BMC Cancer. ;16(1)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z et al (2017) Increased Risk of Mortality by Fibrosis Stage in Nonalcoholic Fatty Liver Disease. Systematic Review and Meta-Analysis\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTamandl D, Klinger M, Eipeldauer S, Herberger B, Kaczirek K, Gruenberger B et al (2011) Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 18(2):421\u0026ndash;430\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHern\u0026aacute;ndez-Yag\u0026uuml;e X, L\u0026oacute;pez-Ben S, Mart\u0026iacute;nez-Sancho J, Ort\u0026iacute;z-Dur\u0026aacute;n MR, Casellas-Robert M, Aula-Olivar A et al (2025) The Prognostic Value of Tumor Fibrosis in Patients Undergoing Hepatic Metastasectomy for Colorectal Cancer: A Retrospective Pooled Analysis. Cancers (Basel). ;17(11)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFong Y, Fortner J, Sun RL, \u0026dagger; M, Brennan F, Blumgart LH Clinical Score for Predicting Recurrence After Hepatic Resection for Metastatic Colorectal Cancer Analysis of 1001 Consecutive Cases. Vol. 230, ANNALS OF SURGERY\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R et al (2011) Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149(5):713\u0026ndash;724\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eClavien PA, Barkun J, De Oliveira ML, Vauthey JN, Dindo D, Schulick RD et al (2009) The clavien-dindo classification of surgical complications: Five-year experience. 250:187\u0026ndash;196Annals of Surgery\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePoultsides GA, Bao F, Servais EL, Hernandez-Boussard T, Dematteo RP, Allen PJ et al (2012) Pathologic response to preoperative chemotherapy in colorectal liver metastases: Fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19(9):2797\u0026ndash;2804\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRobinson SM, Mann J, Vasilaki A, Mathers J, Burt AD, Oakley F et al Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePuente A, Fortea JI, Del Pozo C, Huelin P, Cagigal ML, Serrano M et al (2019) Porto-sinusoidal vascular disease associated to oxaliplatin: An entity to think about it, vol 8. Cells. MDPI\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKnitter S, Duwe G, Beierle AS, Pesthy S, Ritschl PV, Hillebrandt KH et al (2022) Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice. Cancers (Basel). ;14(23)\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarrapita JG, Rocha C, Donato H, Costa A, Abrantes AM, Santos JN et al (2019) Portal venous pressure variation during hepatectomy: A prospective study. Acta Med Port 32(6):420\u0026ndash;426\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMayo SC, Shore AD, Nathan H, Edil BH, Hirose K, Anders RA et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB 13(7):473\u0026ndash;482\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRobinson SM, Wilson CH, Burt AD, Manas DM, White SA (2012) Chemotherapy-associated liver injury in patients with colorectal liver metastases: A systematic review and meta-analysis. 19:4287\u0026ndash;4299Annals of Surgical Oncology\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eCLINICAL AND SYSTEMIC TREATMENT CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSOS\u003csup\u003ea\u003c/sup\u003e G 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eSOS\u003csup\u003ea\u003c/sup\u003e G 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eAGE AT LIVER SURGERY (years)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e63.00 [56.00;70.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e63.00 [56.00;70.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e65.00 [55.7\u0026ndash;71.2]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.527\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eGENDER\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMEN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e67 (62.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e50 (61.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e17 (65.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.436\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWOMAN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e41 (38.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e32 (39.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (34.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePRIMARY TUMOR LOCATION (RIGHT vs LEFT)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eRIGHT COLON\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e17 (15.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e14 (17.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (11.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.370\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eLEFT COLON\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e91 (84.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e68 (82.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e23 (88.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLYMPH NODE RATIO\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e0.059 [0.000;0.142]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.057 [0.003;0.120]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.076 [0.000;0.290]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.462\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eMAJOR SIZE OF LIVER METASTASES (mm)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e45.00 [27.00;60.75]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e45.00 [27.00;55.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e50.00 [27;80]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.769\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eSINCRONICAL vs METACRONICAL LIVER METASTASES\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSINCRONICAL\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e83 (76.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e61 (74.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e22 (84.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.212\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMETACRONICAL\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e25 (23.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e21 (25.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (15.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eUNI OR BILOBAR LIVER METASTASES\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eUNILOBAR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e58 (53.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e43 (52.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (57.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.405\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eBILOBAR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e50 (46.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e39 (47.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (42.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCLINICAL RISK SCORE-FONG (2 CATEGORIES)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SCORE 0\u0026ndash;2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e36 (38.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e29 (39.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (33.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.395\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SCORE 3\u0026ndash;5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e58 (61.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (60.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (66.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATOPATHY PRIOR TO LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNONE OR MILD HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (53.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e39 (51.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (60.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.301\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMODERATE OR SEVERE HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (46.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e37 (48.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (40.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBODY MASS INDEX (BMI)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e25.08 [22.95;27.04]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25.22 [23.34;27.34]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24.67 [22.43;26.59]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.600\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eRAS/BRAF MUTATIONS\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e41 (39.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (43.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (26.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.100\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e63 (60.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (56.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e19 (73.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eOXALIPLATIN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e69 (63.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e52 (63.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e17 (65.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.525\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIRINOTECAN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e39 (36.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e30 (36.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (34.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF CHEMOTHERAPY CICLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7.00 [5.00;11.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7.00 [5.00;10.25}\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.50 [5.00;13.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.750\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF OXALIPLATIN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e544.00 [354.88;841.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e541.45 [366.56;787.31]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e544.00 [340.00;1317.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.661\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF IRINOTECAN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1260.00 [1071.00;1800.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1260.00 [1053.0;1786.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1440.00 [1071.00;1944.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.635\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF CHEMOTHERAPY (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e819.00 [463.25;1271.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e779.88 [459.00;1260.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1071.00 [463.25;1017.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.371\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e \u003cb\u003e(\u003c/b\u003e\u003cb\u003econt\u003c/b\u003e\u003cb\u003e). CLINICAL AND SYSTEMIC TREATMENT CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u003cb\u003eSOS\u003c/b\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003eSOS\u003c/b\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eMONOCLONAL ANTIBODY BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEGFR inhibidtor\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (41.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e20 (76.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVEGF inhibitor\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e48 (58.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e6 (23.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6.00 [4.00;9.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [4.00;12.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.406\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e Sinusoidal Obstruction Syndrome\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eSURGERY AND PATHOLOGIC RELATED CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"5\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSOS\u003csup\u003ea\u003c/sup\u003e G 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eSOS\u003csup\u003ea\u003c/sup\u003e G 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eTIME FROM NEOADJUVANT THERAPY TO LIVER SURGERY (weeks)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e5.00 [4.00;8.75]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e5.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e5.00 [3.00;9.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.723\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEMBOLIZATION OR PORTAL LIGATION BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e79 (73.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e64 (78.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (57.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.040\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e29 (26.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e18 (22.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (42.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eTYPES OF LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMINOR HEPATECTOMY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e57 (52.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (53.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e13 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.459\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMAJOR HEPATECTOMY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e51 (47.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e38 (46.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e13 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLIVER SURGERY DURATION (min)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e267.50 [185.00;330.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e265.00 [180.00;316.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e307.50 [223.00;405.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.119\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATIC CLAMPING TIME (min)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e38 [17.50;81.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e35.00 [15.00;76.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e49.00 [24.75;89.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.120\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBLOOD LOSS DURING HEPATIC SURGERY (mL)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e648.00 [317.50;1080.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e646.00 [320.00;913.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e778.00 [243.00;1391.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.682\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePOST-SURGICAL BILIARY FISTULA\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9 (8.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7 (8.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2 (7.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.628\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e99 (91.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e75 (91.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24 (92.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEMOPERITONEUM\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e12 (11.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e9 (11.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (11.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.590\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e96 (88.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e73 (89.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e23 (88.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLIVER FAILURE\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e15 (13.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e13 (15.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2 (7.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.242\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e93 (86.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e69 (84.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24 (92.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePOST-SURGICAL ASCITES\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e15 (13.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e11 (13.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (15.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.512\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e93 (86.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e71 (86.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e22 (84.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eDINDO-CLAVIEN (2 CATEGORIES)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDINDO-CLAVIEN 0\u0026ndash;2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e80 (74.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e63 (76.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e17 (65.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.182\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eDINDO-CLAVIEN 3\u0026ndash;5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e28 (25.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e19 (23.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (34.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003e90-DAYS MORTALITY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9 (8.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6 (7.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e3 (11.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.372\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e99 (91.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e76 (92.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e23 (88.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eREMOVED LIVER WEIGHT (grams)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e450.00 [138.27;707.75]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e450.00 [159.27;753.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e448.55 [123.52;676.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.937\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eRESECTION MARGIN DISTANCE (mm)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e0.10 [0.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.10 [0.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.20 ]0.00;1.50]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.447\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e \u003cb\u003e(\u003c/b\u003e\u003cb\u003econt\u003c/b\u003e\u003cb\u003e). SURGERY AND PATHOLOGIC RELATED CHARACTERISTICS BY TOXICITY ON THE HEPATIC SINUSOID \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u003cb\u003eSOS\u003c/b\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003eSOS\u003c/b\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL TUMOR RESPONSE BY RUBBIA-BRANDT CRITERIA (2 CATEGORIES)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG\u003csup\u003eb\u003c/sup\u003e NOT RESPONDERS (TRG 4\u0026ndash;5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (43.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e37 (45.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (38.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.358\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG\u003csup\u003eb\u003c/sup\u003e RESPONDERS (TRG 1\u0026ndash;3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e61 (56.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e45 (54.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e16 (61.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003csup\u003e\u003cb\u003ea\u003c/b\u003e\u003c/sup\u003e Sinusoidal Obstruction Syndrome\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003csup\u003eb\u003c/sup\u003e Tumor Regresion Grade\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab3\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eCLINICAL, PATHOLOGICAL AND SURGERY CHARACTERISTICS BY EARLY PORTAL HYPERTENSION (NO vs YES)\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"6\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNO N\u0026thinsp;=\u0026thinsp;85\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYES N\u0026thinsp;=\u0026thinsp;23\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003eN\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eGENDER\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.551\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMEN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e67 (62.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e51 (60.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e16 (69.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWOMAN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e41 (38.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (40.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (30.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eAGE AT LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e63.0 [56.0;70.2]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e64.0 [56.0;71.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e63.0 [56.0;69.5]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.615\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.283\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eOXALIPLATIN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e69 (63.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e57 (67.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12 (52.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIRINOTECAN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e39 (36.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e28 (32.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (47.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF CHEMOTHERAPY CYCLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7.00 [5.00;11.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7.00 [5.00;11.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [6.50;12.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.400\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF OXALIPLATIN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e544 [361;833]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e518 [361;795]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e586 [429;994]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.590\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e69\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF IRINOTECAN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1260 [1076;1791]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1278 [1053;1786]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1260 [1076;1692]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.913\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e39\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eMONOCLONAL ANTIBODY BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.158\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEGFR INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e39 (45.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (65.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVEGF INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e46 (54.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e8 (34.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [4.00;10.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.309\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEMBOLIZATION OR PORTAL LIGATION PRIOR TO LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.022\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e29 (26.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e18 (21.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (47.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e79 (73.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e67 (78.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12 (52.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATIC CLAMPING TIME (min)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e38.0 [18.0;81.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e35.0 [15.0;73.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e54.5 [30.0;88.5]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.054\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e101\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eREINTERVENTION\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.000\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9 (8.33%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7 (8.24%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2 (8.70%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e99 (91.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e78 (91.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e21 (91.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.809\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG NOT RESPONDERS (TRG4-5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (43.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e38 (44.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (39.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG RESPONDERS (TRG1-3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e61 (56.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e47 (55.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (60.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATOPATHY PRIOR TO LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.721\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e101\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNONE OR MILD HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (53.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (55.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (47.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMODERATE OR SEVERE HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (46.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e36 (45.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (52.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBODY MASS INDEX (kg/m\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e25.08 [22.95;27.04]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25.24 [22.86;27.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24.54 [23.83;26.44]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.834\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCLINICAL RISC SCORE - FONG \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.197\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e94\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SCORE 0\u0026ndash;2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e36 (38.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e32 (42.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (22.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SOCRE 3\u0026ndash;5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e58 (61.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (57.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (77.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eSINUSOIDAL OBSTRUCTION SYNDROME (SOS) GRADE\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSOS G 0\u0026ndash;1\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e82 (75.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e73 (85.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (39.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eSOS G 2\u0026ndash;3\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e26 (24.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e12 (14.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (60.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab3\" class=\"InternalRef\"\u003e3\u003c/span\u003e \u003cb\u003e(\u003c/b\u003e\u003cb\u003econt\u003c/b\u003e\u003cb\u003e). CLINICAL, PATHOLOGICAL AND SURGERY CHARACTERISTICS BY EARLY PORTAL HYPERTENSION (NO vs YES)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u003cb\u003eNO N\u0026thinsp;=\u0026thinsp;85\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003eYES N\u0026thinsp;=\u0026thinsp;23\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003eN\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCALCULATED PROBABILITY TO SOS G 2\u0026ndash;3\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e0.21 [0.08;0.32]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.21 [0.08;0.26]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.30 [0.14;0.49]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.018\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab4\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 4\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eUNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT SINUSOIDAL DAMAGE\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"12\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"6\" nameend=\"c7\" namest=\"c2\"\u003e\u003cp\u003eUnivariate analysis\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"4\" nameend=\"c12\" namest=\"c9\"\u003e\u003cp\u003eMultivariate anaysis\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eSOS\u003csup\u003e1\u003c/sup\u003e G 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eSOS\u003csup\u003e1\u003c/sup\u003e G 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eOR [IC95%]\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eN\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c9\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c10\"\u003e\u003cp\u003eOR [IC95%]\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c11\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c12\"\u003e\u003cp\u003ecoefficient\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eGENDER\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMEN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e67 (62.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e50 (61.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e17 (65.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWOMAN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e41 (38.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e32 (39.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (34.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.83 [0.32;2.08]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.701\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eAGE AT LIVER SURGERY (years)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e63.0 [56.0;70.2]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e63.0 [56.0;70.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e65.0 [56.2;70.8]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [0.98;1.01]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.655\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eOXALIPLATIN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e69 (63.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e52 (63.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e17 (65.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIRINOTECAN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e39 (36.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e30 (36.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (34.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.92 [0.35;2.31]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.868\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF CHEMOTHERAPY CYCLES BEFORE\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7.00 [5.00;11.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7.00 [5.25;10.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.50 [5.50;12.8]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.08 [1.00;1.16]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.056\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e1.085 [0.998\u0026ndash;1.180]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.055\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e0.082\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMMULATIVE CHEMOTHERAPY DOSE (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e819 [472;1264]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e780 [471;1260]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1071 [491;1575]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.384\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF OXALIPLATIN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e544 [361;833]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e541 [377;772]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e544 [340;1275]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.043\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e69\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e69\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.99 [0.992\u0026ndash;1.007]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.814\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e(-)0.001\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF IRINOTECAN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1260 [1076;1791]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1260 [1080;1741]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1440 [1071;1944]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.860\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e39\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eMONOCLONAL ANTIBODY BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEGFR INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (41.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e20 (76.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVEGF INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e48 (58.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e6 (23.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.22 [0.07;0.58]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.002\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e54\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e0.214 [0.075\u0026ndash;0.610]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.004\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e(-)1.540\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eLIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6.00 [4.00;8.75]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [4.00;11.5]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.06 [0.98;1.15]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.135\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEMBOLIZATION OR PORTAL LIGATION BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e79 (73.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e64 (78.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (57.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e79\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e29 (26.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e18 (22.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (42.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2.58 [0.99;6.69]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.052\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e29\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e2.819 [1.019\u0026ndash;7.796]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.046\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e1036\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003e2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG NOT RESPONDERS (TRG4-5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (43.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e37 (45.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (38.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG RESPONDERS (TRG1-3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e61 (56.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e45 (54.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e16 (61.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.31 [0.53;3.34]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.563\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL RESPONSE BY POULTSIDES CRITERIA\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFIBROSIS\u0026thinsp;\u0026lt;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e66 (61.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e53 (64.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e13 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFIBROSIS\u0026thinsp;\u0026ge;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e42 (38.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e29 (35.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e13 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.82 [0.73;4.51]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.195\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATOPATHY PRIOR TO LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e101\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNONE OR MILD HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (53.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e39 (51.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (60.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMODERATE OR SEVERE HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (46.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e37 (48.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (40.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.71 [0.27;1.77]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.463\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBODY MASS INDEX (Kg/m\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u003cb\u003e)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e25.08 [22.95;27.04]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25.22 [23.34;27,34]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24.67 [22.43;26.59]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.04 [0.94;1.15]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.434\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNECROSIS CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNECROSIS\u0026thinsp;\u0026lt;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e77 (71.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e57 (69.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e20 (76.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"12\" nameend=\"c12\" namest=\"c1\"\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab4\" class=\"InternalRef\"\u003e4\u003c/span\u003e \u003cb\u003e(\u003c/b\u003e\u003cb\u003econt\u003c/b\u003e\u003cb\u003e). UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT SINUSOIDAL DAMAGE\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"6\" nameend=\"c7\" namest=\"c2\"\u003e\u003cp\u003e\u003cb\u003eUnivariate analysis\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c12\" namest=\"c9\"\u003e\u003cp\u003e\u003cb\u003eMultivariate anaysis\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u003cb\u003eSOS\u003c/b\u003e\u003csup\u003e\u003cb\u003e\u0026dagger;\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 0\u0026ndash;1 N\u0026thinsp;=\u0026thinsp;82\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003eSOS G 2\u0026ndash;3 N\u0026thinsp;=\u0026thinsp;26\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cb\u003eOR [IC95%]\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e\u003cb\u003eN\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e\u003cb\u003eOR [IC95%]\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e\u003cb\u003ecoefficient\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNECROSIS\u0026thinsp;\u0026ge;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e31 (28.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25 (30.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e6 (23.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.70 [0.23;1.88]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.486\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCLINICAL RISC SCORE - FONG \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e94\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SCORE 0\u0026ndash;2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e36 (38.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e29 (39.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (33.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SOCRE 3\u0026ndash;5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e58 (61.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (60.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (66.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.30 [0.47;3.86]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.613\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eSinusoidal Obstruction Syndrome\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMultivariate model constant = -1.621\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"7\" nameend=\"c7\" namest=\"c1\"\u003e\u003cp\u003eMultivariate model Formula: log (P/1-P) = -1.621 + (0.082 x Num cycles QT) + (-1.540 x AcMO, antiEGFR\u0026thinsp;=\u0026thinsp;0 or antiVEGF\u0026thinsp;=\u0026thinsp;1) + (1.036 x Embolization, NO\u0026thinsp;=\u0026thinsp;0, YES\u0026thinsp;=\u0026thinsp;1).\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e\u003cp\u003eP\u0026thinsp;=\u0026thinsp;1 / 1\u0026thinsp;+\u0026thinsp;e(-1 x ((-1.621 + (0.082 x Num cycles QT) + (-1.540 x AcMO, antiEGFR\u0026thinsp;=\u0026thinsp;0 or antiVEGF\u0026thinsp;=\u0026thinsp;1) + (1.036 x Embolization, NO\u0026thinsp;=\u0026thinsp;0, YES\u0026thinsp;=\u0026thinsp;1))).\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e\u003cp\u003e\u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab5\" border=\"1\"\u003e\u003ccaption language=\"En\"\u003e\u003cdiv class=\"CaptionNumber\"\u003eTable 5\u003c/div\u003e\u003cdiv class=\"CaptionContent\"\u003e\u003cp\u003eUNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT EARLY CLINICAL PORTAL HYPERTENSION (HTP)\u003c/p\u003e\u003c/div\u003e\u003c/caption\u003e\u003ccolgroup cols=\"12\"\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c10\" colnum=\"10\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c11\" colnum=\"11\"\u003e\u003c/div\u003e\u003cdiv align=\"left\" class=\"colspec\" colname=\"c12\" colnum=\"12\"\u003e\u003c/div\u003e\u003cthead\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"6\" nameend=\"c7\" namest=\"c2\"\u003e\u003cp\u003eUnivariate analysis\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colspan=\"4\" nameend=\"c12\" namest=\"c9\"\u003e\u003cp\u003eMultivariate analysis\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003ctr\u003e\u003cth align=\"left\" colname=\"c2\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c3\"\u003e\u003cp\u003eNO N\u0026thinsp;=\u0026thinsp;85\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c4\"\u003e\u003cp\u003eYES N\u0026thinsp;=\u0026thinsp;23\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c5\"\u003e\u003cp\u003eOR [ICO95%]\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c6\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c7\"\u003e\u003cp\u003eN\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/th\u003e\u003cth align=\"left\" colname=\"c9\"\u003e\u003cp\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c10\"\u003e\u003cp\u003eOR [IC95%]\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c11\"\u003e\u003cp\u003ep.overall\u003c/p\u003e\u003c/th\u003e\u003cth align=\"left\" colname=\"c12\"\u003e\u003cp\u003ecoefficient\u003c/p\u003e\u003c/th\u003e\u003c/tr\u003e\u003c/thead\u003e\u003ctbody\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eGENDER\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMEN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e67 (62.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e51 (60.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e16 (69.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eWOMAN\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e41 (38.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (40.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (30.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.67 [0.23;1.75]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.418\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eAGE AT LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e63.0 [56.0;70.2]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e64.0 [56.0;71.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e63.0 [56.0;69.5]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.99 [0.97;1.02]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.605\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCHEMOTHERAPY SCHEDULE BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eOXALIPLATIN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e69 (63.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e57 (67.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12 (52.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eIRINOTECAN\u0026thinsp;+\u0026thinsp;5FU\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e39 (36.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e28 (32.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (47.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.86 [0.71;4.81]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.202\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF CHEMOTHERAPY CYCLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e7.00 [5.00;11.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7.00 [5.00;11.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [6.50;12.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.03 [0.95;1.11]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.492\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE CHEMOTHERAPY DOSE (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e819 [472;1264]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e765 [434;1260]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1071 [586;1294]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.382\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF OXALIPLATIN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e544 [361;833]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e518 [361;795]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e586 [429;994]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.283\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e69\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCUMULATIVE DOSE OF IRINOTECAN (mg/m2)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e1260 [1076;1791]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e1278 [1053;1786]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e1260 [1076;1692]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.00 [1.00;1.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.620\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e39\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eMONOCLONAL ANTIBODY BEFORE LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eEGFR INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e39 (45.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (65.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eVEGF INHIBITOR\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (50.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e46 (54.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e8 (34.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.46 [0.17;1.18]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNUMBER OF MONOCLONAL ANTIBODY CYCLES BEFORE LIVER SURGERY\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e6.00 [4.00;9.00]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7.00 [4.00;10.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.05 [0.96;1.14]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.294\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eEMBOLIZATION OR PORTAL LIGATION PRIOR TO LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e29 (26.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e18 (21.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (47.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e79 (73.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e67 (78.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e12 (52.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.30 [0.11;0.80]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003e0.016\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eTYPES OF LIVER SURGERY- 2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMINOR HEPATECTOMY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e57 (52.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e53 (62.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (17.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e57\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMAJOR HEPATECTOMY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e51 (47.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e32 (37.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e19 (82.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e7.52 [2.53;28.6]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003e\u0026lt;\u0026thinsp;0.001\u003c/b\u003e\u003c/p\u003e \u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e51\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e7.78 [2.32;25.99]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e\u0026lt;\u0026thinsp;0.001\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e2.052\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATIC CLAMPING TIME (min)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e38.0 [18.0;81.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e35.0 [15.0;73.0]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e54.5 [30.0;88.5]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.01 [1.00;1.02]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.225\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e101\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eREINTERVENTION\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eYES\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e9 (8.33%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e7 (8.24%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e2 (8.70%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNO\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e99 (91.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e78 (91.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e21 (91.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.90 [0.19;7.05]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.904\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL RESPONSE BY RUBBIA-BRANDT CRITERIA \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG NOT RESPONDERS (TRG4-5)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (43.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e38 (44.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e9 (39.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eTRG RESPONDERS (TRG1-3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e61 (56.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e47 (55.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (60.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.25 [0.49;3.33]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.645\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePATHOLOGICAL RESPONSE BY POULTSIDES CRITERIA\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFIBROSIS\u0026thinsp;\u0026lt;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e66 (61.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e51 (60.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e15 (65.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eFIBROSIS\u0026thinsp;\u0026ge;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e42 (38.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e34 (40.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e8 (34.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e0.81 [0.29;2.09]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.664\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"12\" nameend=\"c12\" namest=\"c1\"\u003e\u003cp\u003eTable\u0026nbsp;\u003cspan refid=\"Tab5\" class=\"InternalRef\"\u003e5\u003c/span\u003e \u003cb\u003e(\u003c/b\u003e\u003cb\u003econt\u003c/b\u003e\u003cb\u003e). UNIVARIATE AND MULTIVARIATE REGRESION LOGISTIC MODEL TO PREDICT EARLY CLINICAL PORTAL HYPERTENSION (HTP)\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"6\" nameend=\"c7\" namest=\"c2\"\u003e\u003cp\u003e\u003cb\u003eUnivariate analysis\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colspan=\"4\" nameend=\"c12\" namest=\"c9\"\u003e\u003cp\u003e\u003cb\u003eMultivariate analysis\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e\u003cb\u003eNO N\u0026thinsp;=\u0026thinsp;85\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e\u003cb\u003eYES N\u0026thinsp;=\u0026thinsp;23\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e\u003cb\u003eOR [ICO95%]\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e\u003cb\u003eN\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e\u003cb\u003e[ALL] N\u0026thinsp;=\u0026thinsp;108\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e\u003cb\u003eOR [IC95%]\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e\u003cb\u003ep.overall\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e\u003cb\u003ecoefficient\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eHEPATOPATHY PRIOR TO LIVER SURGERY\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e101\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNONE OR MILD HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e54 (53.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (55.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e10 (47.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMODERATE OR SEVERE HEPATOPATHY\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e47 (46.5%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e36 (45.0%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e11 (52.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.34 [0.50;3.60]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.557\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eBMI\u003c/b\u003e\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eCATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e25.28 [22.95;27.04]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e25.24 [22.86;27.25]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e24.54 [23.83;26.44]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.04 [0.93;1.15]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.451\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eNECROSIS CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNECROSIS\u0026thinsp;\u0026lt;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e77 (71.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e61 (71.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e16 (69.6%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eNECROSIS\u0026thinsp;\u0026ge;\u0026thinsp;40%\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e31 (28.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e24 (28.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e7 (30.4%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e1.12 [0.38;3.02]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.827\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003eCLINICAL RISC SCORE - FONG \u0026minus;\u0026thinsp;2 CATEGORIES\u003c/b\u003e:\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e94\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SCORE 0\u0026ndash;2\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e36 (38.3%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e32 (42.1%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e4 (22.2%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003eReference\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eCLINICAL RISK SOCRE 3\u0026ndash;5\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e58 (61.7%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e44 (57.9%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e14 (77.8%)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e2.46 [0.79;9.64]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e0.126\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003cb\u003ePROBABILITY TO SOS\u003c/b\u003e\u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e \u003cb\u003eG 2\u0026ndash;3\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u003cp\u003e0.21 [0.08;0.32]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u003cp\u003e0.21 [0.08;0.26]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u003cp\u003e0.30 [0.14;0.49]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u003cp\u003e44.30 [3.44;570.33]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u003cp\u003e\u003cb\u003e0.004\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u003cp\u003e108\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u003cp\u003e40.82 [2.60;640.53]\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u003cp\u003e0.008\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u003cp\u003e3.709\u003c/p\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003e\u003csup\u003e\u003cb\u003e1\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eBody Mass Index\u003c/b\u003e, \u003csup\u003e\u003cb\u003e2\u003c/b\u003e\u003c/sup\u003e\u003cb\u003eSinusoidal Obstruction Syndrome\u003c/b\u003e\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colname=\"c1\"\u003e\u003cp\u003eMultivariate model constant = -3.585\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c2\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c3\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c4\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c5\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"6\" nameend=\"c6\" namest=\"c1\"\u003e\u003cp\u003eMultivariate model Formula: log (P/1-P) = -3.585 + (2.052 x Types liver surgery; Minor hepatectomy\u0026thinsp;=\u0026thinsp;0 or Major hepatectomy\u0026thinsp;=\u0026thinsp;1) + (3.709 x Probability to SOS G 2\u0026ndash;3)\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd align=\"left\" colspan=\"5\" nameend=\"c5\" namest=\"c1\"\u003e\u003cp\u003eP\u0026thinsp;=\u0026thinsp;1 / 1\u0026thinsp;+\u0026thinsp;e(-1 x ((-3.585 + (2.052 x Types liver surgery; Minor hepatectomy\u0026thinsp;=\u0026thinsp;0 or Major hepatectomy\u0026thinsp;=\u0026thinsp;1) + (3.709 x Probability to SOS G 2\u0026ndash;3)))\u003c/p\u003e\u003c/td\u003e\u003ctd align=\"left\" colname=\"c6\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c7\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c8\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c9\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c10\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c11\"\u003e\u0026nbsp;\u003c/td\u003e\u003ctd align=\"left\" colname=\"c12\"\u003e\u0026nbsp;\u003c/td\u003e\u003c/tr\u003e\u003c/tbody\u003e\u003c/colgroup\u003e\u003c/table\u003e\u003c/div\u003e\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"international-journal-of-colorectal-disease","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ijcd","sideBox":"Learn more about [International Journal of Colorectal Disease](http://link.springer.com/journal/384)","snPcode":"384","submissionUrl":"https://submission.nature.com/new-submission/384/3","title":"International Journal of Colorectal Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8196994/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8196994/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eINTRODUCTION\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSinusoidal obstruction syndrome (SOS) and early portal hypertension (ePHT) represent significant hepatic vascular complications following preoperative chemotherapy and liver resection for colorectal liver metastases (CRLM). This study aimed to identify predictors of SOS and ePHT and to develop a risk model for preoperative stratification.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMETHODS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA retrospective analysis was conducted in 108 patients undergoing hepatectomy for CRLM after ≥ 4 cycles of neoadjuvant chemotherapy combined with anti-EGFR or anti-VEGF therapy. SOS severity was graded histologically, and ePHT was defined by thrombocytopenia, splenomegaly, varices, or ascites within 3 months postoperatively. Logistic regression models identified predictors of moderate-to-severe SOS (G2–3) and ePHT. Predictive performance was assessed using receiver operating characteristic (ROC) analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRESULTS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eModerate-to-severe SOS occurred in 24.07% of patients and ePHT in 21.3%. Independent predictors of SOS were anti-VEGF therapy (protective, OR = 0.214; 95% CI 0.075–0.610; p = 0.004) and preoperative portal vein embolization (PVE) or ligation (risk factor, OR = 2.819; 95% CI 1.019–7.796; p = 0.046). The SOS predictive model showed good discrimination (AUC = 0.75). For ePHT, major hepatectomy (OR = 7.78; 95% CI 2.32–25.99; p \u0026lt; 0.001) and the calculated probability of SOS G2–3 (OR = 40.82; 95% CI 2.60–640.53; p = 0.008) were independent predictors (AUC = 0.80; specificity = 84.3%). Neither SOS nor ePHT significantly affected 90-day mortality (8.3%) or overall survival (p \u0026gt; 0.05).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCONCLUSIONS\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMajor hepatectomy and chemotherapy-induced sinusoidal injury are key determinants of ePHT after CRLM resection. Anti-VEGF therapy exerts a protective endothelial effect, while PVE increases risk. Despite their incidence, neither SOS nor ePHT compromised survival, suggesting reversibility with optimized perioperative management.\u003c/p\u003e","manuscriptTitle":"Sinusoidal Injury and Portal Hypertension after Hepatectomy for Colorectal Liver Metastases: Predictors, Risk Stratification, and Clinical Outcomes","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-11 00:45:58","doi":"10.21203/rs.3.rs-8196994/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2026-01-02T19:28:09+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-12-25T23:00:14+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-12-20T22:04:19+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"71499891022146285012119231716981373321","date":"2025-12-13T10:14:32+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"240716552574877298926450914641070379163","date":"2025-12-08T20:02:41+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"333169220657139458419366572888467409392","date":"2025-12-08T17:27:20+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-12-08T08:45:40+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-11-26T00:59:26+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-11-26T00:59:26+00:00","index":"","fulltext":""},{"type":"submitted","content":"International Journal of Colorectal Disease","date":"2025-11-24T21:25:50+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"international-journal-of-colorectal-disease","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"ijcd","sideBox":"Learn more about [International Journal of Colorectal Disease](http://link.springer.com/journal/384)","snPcode":"384","submissionUrl":"https://submission.nature.com/new-submission/384/3","title":"International Journal of Colorectal Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"7b981034-02d2-4d17-ba18-6ddb1f9cea1f","owner":[],"postedDate":"December 11th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-05-20T09:10:05+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-11 00:45:58","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8196994","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8196994","identity":"rs-8196994","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}